var title_f19_19_19760="Aneurysmal bone cyst fibula";
var content_f19_19_19760=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Aneurysmal bone cyst of the proximal fibula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Frontal (A) and lateral (B) views demonstrate an expanded lesion of the diametaphyseal area of the fibula. The lesion is trabeculated and does not cross the physis. This lesion is radiologically characteristic enough to allow a confident diagnosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Daffner RH. Clinical Radiology: The Essentials, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_19_19760=[""].join("\n");
var outline_f19_19_19760=null;
var title_f19_19_19761="CCK sphincter of Oddi manometry";
var content_f19_19_19761=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Sphincter of oddi manometry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 290px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEiAdEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKK4v4yS65B8OtTfwqb0awJLcQmyjMkwBuIw5VQDn5C2eOma84sbTxzpnie3ZdS8VXtnbeK0sVS5TfHJp7wlnlfEY3KGwA+dq9Bg0Ae90wyxiTyy6CTG7bnnHrj0r51trL4g3k2mvc6r4xgF+usJdokewW6wtutQuY8oXPRjyw4U44p6aR441vxX4S1JZLvTdRPg8xX17daW0ymYvloWUlQsjdcZz7UAfREciSoHidXQ9GU5Bp1fJtvf+JvCXw80O21GTxDotnZ+Grue3jtYWjZdR86TaLkYyqbNhG4AHJ5zX0z4LuLi78HaFc3rvJdTWEEkrv95nMaliffJNAGzRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRWfqusWOlPZpfTeW93MtvAu0ku7EADjpyRyar6j4htNOvYra6hvVMs0dukot2aNnkICjcBjqefTnPQ0AbFFZGj67Fq1xOlra3ghilmgNw6ARs8UhjcA5z95WHTtWvQBlav4c0TWriCfWNG03UJ7f/UyXVqkrR85+UsCR07VqgYGB0oooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorn5/GOh2/iM6FcXvk6kZI4USSNlWR5EZ1VWIwx2pzg4BZQeWAPQUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc94ysNT1G1sY9Kis5GhvIbp/tNw0QxHIr4G1GznBHbHvU1zpVxe+J7G+u2i+w2ELNBCrEk3D5VnPGMKmVX18x8gYFbdclr32tvFmk2enalexzTyC6uIgyGKK2i27uCufnbanX+JiPu0AO0jw/cW3it9TFnpunQFJ1kFlIxa8eSRWEko2KAwwx6scuecddbWPDmia3LHJrOjabqEkY2o13apKVHoCwOBWB4ee/svFL2esSyzy3pvLq1ljvGki8hZxtVoyoCFUkjXjcODznr0msavbaRFHJdx30iyHaBaWU10QfcRIxA9zigDB8BWNppmo+LrPTbWCzs4tWTy4LeMRxpmytScKAAMkk/UmuurkfAN7FqOo+L7q3W4SKTVkwtxbyQOMWVqOUkCsOncDI56GuuoA+d7Pxj4l07x1GPEF9qN39t1CaLTH0m7tp7C5QA7IGhC+Yh4wWJ3A8mm+F/GWuta/D7Xh4nm1TU/Eeq/Y9R0YiPyYYmL72jjC708oKuSSc9+te52XhjQbDVJNTsdE0u21KTJe7htI0lbPXLgZOfrT7Tw9otnqs2p2mkadBqU2fNu4rZFmfPXc4GT+JoA4PwJr+s3Hxf8baHq+sQ31nZRW0lnFFCsSxhwzFQMkkgYBJPOM4HSvUKxbHwn4csNVbVLHQNIttTZmY3cNlGkxLZ3HeFzk5Oeec1tUAFFFFABRRRQAUUUUAFFcrr+v6jZePvCmiWNvby2WpR3kt7K5PmRLEibNnPd3AOQeK6qgAooooAKKKKACiiigAooooAKKKKACiiigAopFZXGUYMMkZBzyDg/rS0AFFFFABRRWL4z8QReF/DN7rE0ElytuFCwxnDSOzhFXPbLMOe1AG1RRXKXuuXMPxH07SxIq6e9myyJ8pMlxJueL3G2O2uPQHf3wKAOrooooAKKKKACsjX/EemaC9uupzmJp1ldMKSAsaF3YnooAwMnHLKOpFXNXuDZ6Ve3IIUwwPICegwpP9K5DQ/Dmpajfaivju2sNThhhgsreZkVheqjmUztFjCEsYgV6boSQApWgDG0zwz4mktkMM8+n3EluusyzSXb4n1WQrmGRFYkQRiMqUztKyrgFk3Vpz+JPGdlJOl34ZgkuLiMTWMNrJJLHGE3GaOacLgOVVTH8oDNIFwdrPXoFFAHn1rpX2z4XTX50+FtZu7G5v4vNi2yRSzn7QEyRuXDiLPTmNf7oxrz+ONLt7G9upUuWjtXjU+Sgl85GGTLFtJ3Iu2XP8Q8mTjgZ6quYg8FaZaa1pN5YqbW1062+zR2UY/dHaHWNsdiqzTj38zJztFAHTAhgCpBB5BHelrhNENp4EivtG0/RdW/si1kFxbpa2xkitrZo13lWLZciRZWKLmUl8hCCCbukeItWjNvJ4l0v7Ha6g8X2WWL/l2MnCwXALZEm7aNwG3dIF7ZYA66iiszStd03VhMbG53rHKYdzIyB255QsAHU4IDLlSVYAnBwAadFFFABRRRQAUUUUAFFFFABUS20C3T3Kwxi5kRY3lCjeyqSVUnqQCzYHbJ9alqh4g1OPRdB1LVJkLxWNtJcsgOCwRSxH6UAOstJ06xuZ7my0+0trickyywwqjyEnPzEDJ5JPNXaw/D+qXtzf6hp2qxW8d7aLFITbsSjJIDjrzkFHHvgHjOBPrGqXdhLGtpoWpamrDJe0e3UIfQ+bKhz9AaAM/wAJ/wDIe8af9haP/wBILSugtbiG7t0ntZo54HGUkjYMrD1BHBrmvDFld3Y8Uy6pYXumJqt7vjiedFmEf2SCEsHhdth3Rvghsjg8UHwtc6XcSt4PvrTR7acKJbN7LzrdWUY3xIrp5bEYB5KnaDtBySAaHirVbjTbOGHTI4Z9YvpPs1jDM21Gk2sxZyOdiqrOcckLgZJANTwdNqMM+p6TreoNqN9ZPE4uWhSIyxyRg7tqcAeYsygdQFAJY5YpoPhq6tNbm1bW9Ym1a9WIWtqTH5McEI5JMakqZnPLyAKDhQqoBg2tb0a8u9QhvNJ1VtMuCn2e5YQLL5sOcjaG4WRSW2sdyje+UbI2gGV4qvZI/F2hGK8uIbewkSS6gichZ/tLG3hVwOo3F257oDXWxXEM0k0cMscjwP5cqqwJjbaG2sOx2spwezA965lvBkL2V8JdW1WXVLwwNLqTyqZQ0Ehkh2R7fJQKx+6sYDcltxJJrab4U1nSbi8udO8TF7m+nNzdfbbFJY5ZMBAwVCjLiNIkADYwmSCSTQB2dFctHoPiGUIL3xjdoV5zYWFvFuJOSG8xJeB0GMEDqWPNR/8ACOeIgW2+Nr8JGR5A+w2pLDqROSnz88DZ5XGOp+YgHW0Vyp8Oa5FCptvGmqvcqcg3dpaSRNkgkMqRI2MZxhxjPU9Kgi8K67IY/t/jjWJBCQ0Rtra1gZmxyZP3TB+ScABVAxkMw3EA7GiuVXwne2+Rp/i3xDbhxul3vBc+ZJ/FIPOifZn+4m2MfwovOWN4QvpZklufGXiSWWMYjKtbRBcjDZRIQr54++GK9VIPNAGZrs0o+I9rdbmS3s3soCzBdpMwu0ZQeuSWtyfovvXoFcsvgqxTSb+zS81Hz7y5ivHvpJhJOs0RjMbAuCMKYkwpBXg5Byctg8GmC5F2niTxCb9xtubhrlG+0KCdqmMp5UYGeDEiHrknLZAOrorkj4Pu5GU3PjDxPOPuOPNt4g8eQSn7uFducffXEg7OKT/hB44uLHxF4mtVQYgUak0whzw2PND+Znj/AFm/b/BtycgHXUVyA8EMJ/tQ8U+J/t6sfKuDeKREhzlPJ2eS45PLxs3T5sgEX4vCttFYyWialrnkyHe5bU5mkL8fMJCxden3VIXk/LQB0FQJeWr3stmlzC15EiySQBwZERiQrFeoBKtg98H0rmf+EEshLmPWPEyRBGCwjW7khXJBMm4uWJ4A2sxQc4XJJNyTwX4fltIbeXTkdYyWLmR/MlLKAxlkzul3bULby24opOSoIAOhormB4I0ndEXn1yURtkLLrd7Ircg4ZWlIYcDg5FPm8FaPJG6qdUg3SeZut9VuoWXr8qlJAVTk/IML044FAHSUVzaeCdAS4jlWzlAVQrxfapvJmIyN0sW7ZK/PLuGY8ZJwKaPA+igx4/tTCNu2nVrshxx8jDzMNGMcIcqMnAGTkA6aiufuPBvh+aFo/wCzYocsHWS3ZoJIiO8boQ0ff7hHU+pqCDwLoUU+/wAq9liKFGtp7+eWCQkYLvG7lWcjq5BYkkk55oAzfg9qMWo+GLuSIOCdSurkhhggXMhu0/8AIdwlb/jc7fBevkag+mY0+4P25Axa2/dt+9G3nK/e4544qK/8IaNeyQSfZ57RoYlgX+z7uay3Rr91H8l13qvO1WyFy2MZOYYPBGhJkTwXd+px8upX9xerwdw4mdh1AP4UATfD+6+3eBfD1yZ5bh5LCAvJM26Rn2ANvP8Afznd3zml8Yate6ZZ2kGkW8Vxq2o3Is7QTHESOUd2kkwQSqJG7bRgttCggtkF34Q0O6umuHsQkjFmbyZXiUuxJMhVGA8zJb58bvmPPJp+neFdE0+6trq206L7ZbhxHcykyzDd94mRiWJIyMkk4JHQkUAO8Ia2niDw9Z3+EjuWQLdW6tk21wAPMhb0ZGypB54rL+IMcWoN4f0O5ZTbarqPkzx7sM8ccEs2Bj/aiQH61p6j4W0bUb77XdWQMzOJJfLkeNbhgAF85VIWXAVQA4YDAxU2neH9J067N1Z2MMdztKCYjc6IcZRSclU+UfKMDgcUAZfhLX438B2uqa3dpDJZwNFqM07BRHNCTHOWOAOHR+cAVzd3qVjcWN14z06eK7t4NVs5Y52G1YbbYkM24cFTGk90xDcq2cjjFdzLoGjzXpvJtJ0+S7MqzGdrZC5kXG192M7htXB6jaPSrTWFm1rcWzWtuba43+dEYxsl3/f3DGDnJznrmgBNVvodL0u8v7tttvawvPI3oqqWJ/IV4f4oudc8PfD/AFHSX1iWxv8AU7W01K1uFnImjlLh9RVGzkqoVpeMbRKw4UDHrl14O8N3cHk3ehaZcQ9o5bZHUcEZAIxnBYZ68n1Nal7p1lfSQyXtnbXEkG7ymmiVzHuUq20kcZUlTjqCRQBzPjfxrpmiCTSbfU7RPE11GI7G0ZgzmWRljiLL2G91POMgMRnacYkPje/NppmlaRJYa14lgvJrbULV50SdoLdpUebYpAR5DGu3cFTdIASo5He6XpGm6SkiaVp9nYpIQzrbQLEGIAAJ2gZwAB9BT4tNsYb17yKytkvH3F51iUSNuCBstjJyIowfXYv90UAcPB4I1HUIzqWo6gbXV9TzHq0DA3EMlqX3Lbqu4KrRqNiuAR88rFWL5HodFFABRRRQAUUUUAFVdUsLXVNPnsr+ETW0y7XQkjI9QRyCDyCMEEAjBq1RQByN54FtNQ+zR6pqusX9pC3mNbXFwpSSQAhZCwUOrLuyCjLyA3JANaV94R8PX4thdaLYMba3+y27CFVa3i4wsbDBTGBjaRjHGK3KKAOKgv8A/hDNQ+w69rc8ukTQJ9ivdVljXbKpYNA0oVcnbsZd5LtiQ7mwcbfhzUNV1JZLjUNPt7KzYn7MVufNkmTPEjAKFQMOQoZjgjODkDaooAKKKKACiiigAooooAKr6jZQajp91Y3ieZbXMTQyp/eRgQR+RNWKKAMrQ9FTSpLmZry7vrq42CS4uihcqgwq/KqjAyT0zlia1aKKACiiigDxvRfjFJqPjG90y4g0jTorO6lglsr25kivzGgJ81VMexsgZ2Bicd6n0b4qatPH4X1jVdEtLbw14lvhp9i8dyz3MLuWERlXaFw2w/dPy579+hPwx0yfXrHU9W1TWdWFjM1xaWt/OkkULnPQhA7AZ4DMQKi0b4UaHpV/psiXmrXFhpc7XOnaZcXIe1tJDn5kXaGJGTjczYzxQA2w8Z69F8UYfCutaTp6wXltNd28tldNLJDEjYVp1KgLu6DGRnjmvQ64Lwx8M7Xw94uvPENt4g8QXF1eytLdQ3M8TxzZUhVbEYbauflG7AwK72gAooooAKKKKACiijvigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiio7meG1t5bi5ljhgiQySSSMFVFAyWJPAAHOaAJKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOd8Z3V9Zx6TLY3XkI2pW0M6eWGMqPKqlcnpwT0qpr32tvFmk2enalexzTyC6uIgyGKK2i27uCufnbanX+JiPu1v6po+mausa6rp1nfLEdyC5gWUIfUbgcdBWffavpulasomsriO4neGzFyloSr7mxGm8DkAufYZY8c0AZPh57+y8UvZ6xLLPLem8urWWO8aSLyFnG1WjKgIVSSNeNw4POeu/rE+txSxjRdP027jI+dru/e3Kn0AWGTI98iqHhufSJ9RvptI0X7MzTTQzXqWyRrNJHKyOCwO5vnVuo55NdJQBieGNXu9UbVYNSsoLO8067FrIlvcGeNswxShgxRD0lAxt6g1t1zXhP8A5D3jT/sLR/8ApBaV0tAGP4vvLqw8M6jPpzIuomIxWZkUsv2h/kiBA7F2UGpfC93Lf+GdJvLhoXmuLSKWRoRhCzICdo7DJ4FZ+sQNqXi3SbOWRxZWsT38kSniWVWRYt3HKqS7Y/vKh/hqTwH8vhHToQwb7MrWxOSeY2Mff/doA36K4vwpfm48deJVl1OeYTLG1taSSfu4lheSGTylx/fUFyCcFkzjIz2lABRRRQAUUVFdTpa2s1xLkRxIZGx6AZNAEtFcx8O9bv8AW/C9jP4gWyt9dZGa7tbVjtjIldBhSSQPkI5PUH0roby6t7G0mur2eK3tYUMks0rhEjUDJZmPAAHc0ATUUyGWOZC0MiSKGZCVOQGUkMPqCCD7iuc8dalqWmLoDaXPYwLcavbW10bsHDQOSGVD2kJ2hfc470AdNVW31Gxub67sre8tpb202fabeOVWkh3jKb1Byu4AkZ6jpVqvHNQbVbK9udY0+CUJqurMdSvoZAEto7C7YKrcghZIImjOMjdwcb+QD2Oiqes6pZaLpV3qWq3CW1jaxmWaZ+iqOp9/oOT0FWLaeK6t4ri2lSWCVBJHIjBldSMggjqCKAJKKKKACisLR/E9lqvijxBoNvFcpeaIbcXDyIBG/nR+YuwgknA4OQMH161pavqFvpOk3uo3rMlrZwPcTMqliERSzEAcngHigC3RVfTbyHUdOtb21JNvcxLNGSMEqwBHH0NWKACiueTxPC3xAl8KGBxcJpaaoJt3ysrStGVx2IKg59/augZgqlmICgZJPAAoARZEdnVHVmQ7WAOdpwDg+nBB/GnV5/8AB66OoWviPUpAUm1HU0v2iOf3Sy2ds8aZ7kRlAe27djjFd3d3MFnaTXV5NFBbQo0kssrhUjQDJZieAAASSaAM/wD4SLRze2FoupWjXN/JPFaxrICZnhz5oXHUptIb0IxWrXgvgPz10Tw3dXe83en3aXI4wCNR1CZd3/fBX6bvevcdTvYtN027vrlgsFtC80jHsqqST+QoAs1W1O+ttL0271C/lENnaRPPNKQSERQWZuOeACa5j4P3M1z8MPDRui5uIbNLaUvndvi/dtnPfKGma94iup9XutBsdHubqJnt7WS7jIZEaRlMyOBzHtt3Eiu3yscrkNtDAHT2Wp2V7o8Gq21xG2nTwLdRzk7VMTLuD84wMHPNcFNr9tr3xB8IajoeqCbSEtZPMMTny5xdK/lE+6taSDBGQWxweKo2+oXus6J4b8HWNpHP5tvs1a5DhVs4beZYnUoQdxl8uaMAHgqTggEjf8RaBZ6HYajq1pJMjyanaX9zLLMAsEKTo0oDH7sQVp5CCeDJJyAQAAO8XnXda15dF8N6n/ZLWdqL6e88oS7pHYrBEVLDKHZKzD/ZTnBIPP3lnP4zl/4Q/wAQyz3R0/7XPe74jGtwA5SyMwChHDIxlwo2mSDoNpUdh4I8y8TVNceRWh1a68+0VH3qLZUWOJg3cOE83jp5uOcbj01AGL4K1dNd8I6RqaTQzG5tUaRoZRIokxh13DqVYMp9wa2q89v7jUND8Vaho+jwOJtemhvLSbyi8UHRLxjgbU2oiOAx+eSYcHLU238eT6dJNp+qQLeXWmX5tdWuIpEjFnbuym3uXXPRkkiZiMKNsx48vbQB6JRXnWt/EqSyXV47LQ5Li7gk8vTkluViXUQkwhuGVsHZ5Lbi24fdAbocj0RWDKGUgqRkEcgigBaK5a/8d6DaXklvHdC8a2kKXz2pWRNPUMEL3Bz+7UMcHPIw7Y2xyMtO/wDENz4huINN8JyX9qXkZpdVOnMYFhWMlXieRRHKGkMS/KSWQuVxgOoB2tFefaX/AMJF4R8RafYajNceINK1mTNxqs8wRrK6ERyiwgECGQouxVPyMXyTuWvQaACiiigAooooAKKKKACiiigAooooAKKKKACsW70qe98UWV9ctGbCwiZreIEljcPlS7DGBtTIXk/6x84wK2qKAOU0jw/cW3it9TFnpunQFJ1kFlIxa8eSRWEko2KAwwx6scuecddvWbC5v4o1tNXvtMZTkvaJCxf2PmxuMfQCrdtcwXUfmW00c0eSN0bBhkdRkVLQByPgK2ltNR8XwXF7cX0q6smbi4WMO+bK1PIjVV4zjhRwO55rK8RRa7D8a/CNxaXeovoNzYXcN3ax5+zRyIAyyP23NvAGefk471veE/8AkPeNP+wtH/6QWlUPiN4KuvFcuiXmk6/c6Dquk3DTQXUMQlyrLtZChIBBwvXIwCCDmgDQtJXk+I2qxFl8uDSrNguOQXmuQTn0/dj8qzRf3Vh4W1WCwlig1SPVpLNGmQusT3F0DGxXI3AJPG2M+1aHgfwTpPg6C7/s03dxeXrLJe317cNNPdOoIDuxOM8noAParl34Z0y61yLVpI7hbtGViI7mRIpSudrSRBtjsOMMykjaOcAUAcJ8Sorvwz8J5tYuLmKDWtNjurs3FtwiXNxHMpEZYZ2+bONueTtXOTXp9lMtxZ286OHWSNXDD+IEZzUep6dZarZSWeqWdve2cmC8FxEskbYIYZVgQcEAj3ArGt/Dl9bReVa+JtVjhQkQReValYkwNqcxZYLjAJO7HUk80AUfH+qazpN3o11pVxbJYRTeZqsc8LSH7IHjDyKV5DIGz6YJJztwdrxJrcWk6M11CUnuph5djApybqYqSkagdc4JJ6BQzEgAkRaNoMtjqEl/f6xqGqXbReShuREiQqW3MESNFHJC8tuOFXnrmHQPCVjod3FLaz3ssNtAbayt7ibzUs4yQXWNiN5DFV++zbQoVdq/LQBzDQeK7PUPDGqeKdXt1S2ulspLXTxIsdwZUMXmzHcFfdJsZV2KI95GWIydnx3rNnJoHiXR03vqH2B41gZWj84yrsVUcgBjudAdpO0umcbhnodd0uHWdKnsbiSeJZNrLLA+ySJ1YMjqezKyqRnIyOQRxWbH4R0tlsG1AT6ld2U5uo7u7lLSmQkMSSuBtyqEJjYDGhCjYuADhfAsiRfG/wAVWEayg2tiEkJPBd7qW6/9Bu0x+NXfGxtta8X3fhS/u5Xt9Yt7KEWbDcm2J7iWd154JTylLYH8HJ4x3Gu6HHqz20y3l7YXltuEVzZyBXVWxuUhgVZTgcMpwQCMEAh+h6LbaOtyYJLqee6l86ee5naV5HwBnk4UYAwqgKOwFAHL/Bee4ufBJmvoJba8m1C8uJraaMxyQvLcPKUZTyMeZ3AJGDgZp3xPK3EOmwwBbi90+ca19kQB5Xjt/myqdTliqjA6sO9aepeC9NvtVuNS+0ara3krpKGtdQmiRJlQoJRGG2FtuAdylWCgEEZzq6Lo9tpMUvlGSa6nbzLm7mwZrh/7zsABx0AACqMBQAAKAOG1nxxZarq/heTw3fzXNlHqzR3csCuscq7Vg25OA6b7uFgw3KdoIzjIspDDL8F9TkkQyQXVheXpCc7hKZJeP+++K6K+8IaHfXl3dXNkWmuoPs8u2aRF2/IQyqrALIPLjxIoDjy0w3yjGxYWkFhY29nZxiK2t41hijHRUUAAfgAKAPNNA1k618J9C1aWWS+bUdYtrgFt3yb9TVtg3chYwdo7YQY4rJ1nU/Gnhayu7W3aGy06x0aeDTjcIsxmmglTbMWB4DQMMK2DuSQkYALej2fg3RLOdZLeC6VVujeJAb6doElyxysRcooy7HaFAzg4yBi/reh6drf2L+07czizuBcwjzGUK4Vk52kbgVdgVOVIPINAGB408U6hpOp2elaLpkl9e39tL5UyxPLFazlkWBrgJysLFnLP2EZxnszwR44/t/WdS0bU9On0nWLPDi1m5MkWFBcEfL94ngE/KUJ+9gbmh+G9N0SeWexW6M8sMcDSXN5Nct5cZYooMrsQAXbp1zznAqTxBoOn6/bRQ6nFKyxP5kbw3EkEiNtKna8bKwyrMCAeQSDQB5trsd5b3+reJdNuGt9O/tSKXUbqGRkKxWlxbxOrD+JPK+2Fv+uaiu48V6nYXfw41jU4J47jTptLmmSWMhlkQxEgj1yDWtoek2mh6bHYackq26O8g82Z5nLO7O7M7ksxLMxySetZA8D6GJZWEeoeXLdNePb/ANp3PkNK0hlYmHzNmC5LFdu05ORQByM+q+KNNSykZZNN0vw15cOq+dbqYdQhMgQzI/VVjgBnJU4BYI2SrAdzrvivQ9Bv7Sz1fUYrW5ulZ4kYE5VerEgYUDk5OBgH0ONe4hiubeWC4iSWCVSkkcihldSMEEHggjtWX4d8Oab4dhaLS47hVKJFme6luGCICEQNIzEKMnCg4GT6mgDyLxbql9f+P9C1/wAJyPNZXer2mjy6jagSwS2UZSeTEq5G1pJJIyQSCYyuRgiu8+JXiO2gt5/Ctr58uv6zYTpZRQYJVmKxBm5yoBkZ844SGU/w4PZXVpDdWb2syZgddhVSVIHbBGCpHYjBHas7Q/DenaLeXl3ZfbXubtUSaS7vp7piqFyqgyu20AyPwuB81AHDxa0uifHG18K2YEVrqOnSahLGqjDFViii5PTCwSDjrkZ6Cma14sbxBD4g8Jzpaw6jqFybCxtknAlns2ka3nm56snlXLkAcKEHU8+ga3oWn60IDfRy+ZBIJYpYJ5IJUYBhw8bK2MMwIzggnNS6PpVno+nxWWnxskEZdhvkaVyzsWZmdyWZizEkkkkk5oA8n1yC70DUviNql7YSppKahpGoW80h/dyrG8UkzDGSNrKxPFdBaS3vj+bTLTXtB1HTtNs4vP1S3ulaOG5utoC245/fwqTIzEjYxWP72Tj0K5ghureW3uYo5oJUMckcihldSMFSDwQRxipKAPJFm1WbWpdN0NxLfaBe6hqVxaROF8x5J1khhcsQB5tvcXAUtxuAbPyV3ngywu7WwurzVYxFqmqXLXtzErBhESqokeRwSkUcaEjhipPet7A3ZwMnjNLQBjaH4csdF1DVryyNwZNSm86RZJSyR9SVjXoql3kkI/vSMemANkjIwelFFADY40ijSOJFSNAFVVGAoHQAU6iigAqrNptjM9281nbSNdxCC4ZolJmjG7CPx8yje/B4+Y+pq1RQBQstG02ytNOtrWwto4NOGLNBGP8AR/kKZT+6drMuRzhj6muQTwDfWYX+x/FGoWIsgsWlRAF4LWH58xSRb9k4w+1SQGVY4+SQzN31FAFHRtJtNHsLe0so9qQQpAHb5nZVzjc3VjkscnuxPc1eoooAzfEemtq+jXFnHMIJ22yQTFSwjlRg8bkAgkB1UkZGcYyK51fCeuSTzSXfjC/db4Fb6OGIRKq/wi1wSbfuC2XYhidwYK69pRQBw1hZeIPCN3LDZxX3ibR7go4ae+BvbZwio/MzBHRiu/AKbWZgAQRt1dF8Sz3GqPp+uaTPotzIwNks8qyLcoULbQ65QSrtk3RhmIC7gWXJHSCqOsaVZ6xarb6hE0kaSLMhSRo3R1OQyupDKfcEcEjoTQBeormf+ETaOLy7TxF4gt4wPlH2tZiv/ApVdj+JNPbwu7I4/wCEg14OfuuLlcoPQDbg/VgT6GgDo6K5w+EbNt7S6jrzysMB/wC17lMemFVwv6c981oaPo0Wl28UUd1qFwI84a7u5JmOfUsTn8elAGnRRRQAUUUUAFFFFABWP4xtru98I65a6dkX09jPFBg4PmNGwXn6kVrsQoyxAHTmomurdZfKaeIS5A2FxnJ6cUAcz4MiQ6vrN3ZWM9jpkyWyRRTWzW5MiIQ52MAehjXOP4fatfWNBtNXkje7m1KNoxtAtNRuLUEe4idQT7mrcOoWU909tDd28lwmd0SSqXXBwcgHIwatUAZuhaJZaHDcR6etx/pEvnzPcXMtxJI+1UyXkZmPyoo69BWlRRQAUV872fjHxLp3jqMeIL7Ubv7bqE0WmPpN3bT2FygB2QNCF8xDxgsTuB5NN8L+Mtda1+H2vDxPNqmp+I9V+x6joxEfkwxMX3tHGF3p5QVckk579aAPoqivFPDGvX9t8cYtHHiq51bRr+wlniEk1vcJLKu1v3YiAMKqCw+f7209eK9roAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOQ+IyRmHRZTa3txNBqVvMv2a3mm2Ksql2IjB/hz1/CnazpUWr+L9MT+zkW2tduoXN21vgyyKcQRhyMkhgXODkbEB4autrnNc1fUtO1jTraG3spor65SGNTK4l2Y3SuRtwAqhj15+UdSKAMrwvbyWHime305b+TTZWvLm5a9svJ8iZ594WOTYu9WLyd34UcjjPR6xpd3fyxtaa7qWmKowUtEt2Dn1PmxOc/Qisvw34gu9R1m8s78Q2jxy3CxWz28scrxxzGNZFZsK6lQrErkDeK6mgDmvBs179p8RWWoahPqH2DUFghnuEjWQobWCXB8tFU4aRu3TFdLXNeE/+Q940/wCwtH/6QWldLQBkWXhjQbDVJNTsdE0u21KTJe7htI0lbPXLgZOfrT7Tw9otnqs2p2mkadBqU2fNu4rZFmfPXc4GT+JrUooAydK8NaFpF5Pd6ToumWN3PxLNbWscTyc5+ZlAJ555rWoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqB0qBtdGrO0j3CW/2aNWI2RKW3MVGM5YhMnP8C4xzm/UN7dQ2VnPdXUgit4I2lkc9FVRkn8AKAM210JYtZXUri/vbyaNJIoEnMeyBXZWYLtRSfuKMsWOB15ObGsaJpWtxRx6zpljqEcZ3It3bpKFPqAwOKZoutW+r+esMdxDNAV8yG4jKOoYblOPQj+RHUEU3WPEeiaJLHHrOs6bp8kg3It3dJEWHqAxGRQBz/hCLTfDj+OPs1tDY6ZZ6kJTFawYVFFhas21EH1OAMkn1rptL1ex1PetnPmWP/WQSI0U0fpvjcBlz1GQMggjgg1geAr+z1PUfF95pt3b3lpLqyeXPbyCRHxZWoOGBIOCCPqDWvf6HDNq8Wr2ZS11VIzA1wIlYzQk58t+5UH5hggg9DgsGAKmpSaq+u3I0u5B+yWkUospAojuGd5NwZsblOIwFIOASSQ3Snad4hmudVitrrSL2xtrhStvPcAAySrkuhUE7eBlWJ+ba+MAKXtaFpVzp0l5JfalLqM87LiWWJI2VFUDadgAPzb2zgcNjnGTd1GxtNTspbPUbaG6tZQA8UyB1bByMg+hAP1FAHPT+PdBtree8vLiS10mMNt1OeMraylfvBH/AIvY4w/8BbBx1VQSWdtJYNZNBH9kaMwmELhdmMbcDtjjFZMWh30MYii8RaoIkXbHuSB2A7bmaMlsep5Pck80AbtFYLaFfTKoufEmqsNwdlhWCJTg5ABEe4Dp/Fz0JIJFN/4R66UyCHxJrccbkNs3QPtPfDPEWAPpnHoAOKAOgqjq2rWOkRRvfziPzW2RRqpeSVsElURQWYgAkgA4AJ6AmqX9h3G2bOv6uZJG3B90IKHjG0CPbgY6EEHnOTzT9O0MWurSaldahe6hdGIwxG58sCBCQWVAiKPmKqSTknaOeKANKzure+tYbqyniuLaZQ8c0Th0dT0KsOCPcVNWHP4ZsxqMmoaZJLpN9Mf9ImsVjU3P/XRWVlYgnIYjcOQDgkEk8PyXEifbtb1i4hTkRLMluC2MZLQojnvwW2+3AwAblFcrd+BdKvWjN7Pqd15TGWAXF7JN5E2crNHvJ2yL0Vh0BPqcuvfB0V+6y32t69LcK6ETR3nkEIrq5jCxBVCsUG4gbiDjdjGADqKKxLjwzZT53XOsLkAfJq10mMfSSqkXgbQYI447SC8tIo2DiO11C4gUsP42VJAGY5yWOSTySTzQB01Fc9H4Ts42Vvt2tNJGd0TSanO/lN6gFiG6n7wb06cU7/hFbBiHmudXlm7ynVLhWJ5yQFcBc5PCgDpxwMAG/WHY+LdA1DWE0qx1ezudQdJJBDFIGO1GCsSRwOScZ67Wxna2IJPB2mO5LXGtFW++n9s3e1+COR5voTx0PGc4GNK50LSbrTINNudMspdPtwqw2zQKY4wo2qFXGAAOBjtxQBo0Vzsng3RmijhjS+traMFY7e11G4t4UXGNqxxyBQuOMAYFNj8D+HYYxHa6cLRFO5BazSQeWc5ymxhsJ7lcZyc5yaAOkqjruqW2iaPd6le7zBbRl2WNdzueyqvdicADuSBWIvw/8MKXK6YA8pJuH8+Tfd5OSLht2ZxyeJCwAJHQ0tt4B8M21xbTQaWqNbTCaBfOkKQkNvCom7aqB8N5YATcqtjKqQAOt/FhTUraz1vRdT0b7W3l2090YXhkfjEZeJ3COc8BsBjwpY8VP4pubxLzQbPT7xrSS7vtsjrCJMxpDLIVOQQASiqTwcEgEEgjW1OwtdTsZrO/hWa2lGGRvrkEEcgggEEcggEcisrSPCOi6RqbajZW0v25lZXnmupZnkzj5mLsdzYUKGOSFG0ELxQAyz1PVofFX9k6pBYNaz28tza3VvI4dhG0QZXjZSFOZeCHOQucDoK3jxrzULSPw9ol9Pp+r6grOl5Cm77LFGVLSNyOMlE2g5JfjgMy7er6RZavFEl/EzGJi8UkcjRSRMVKko6EMpKsykgjIJHQmoNG8Pado91Pc2Uc5uJo44XlnuZZ3MaFiigyMxABdzgf3jQBX8N+IH1W5u7C/wBNudM1azjikubeUh0xIXCtHIvDoTG+DhW45VTxWBBZa9d3eqeI9NvbxLlbuWO10q4mP2a4t4tsexlIIjZ2jkkWRMEeYu7eBsrq9W0HSdXlik1TTrW7kjRo0aaIMVVsblyexIBx6qD1Aq5ZWsFjZwWlnEkNtAixRRIMKigYAA9ABQByo+IGm+a9tJY6tDqA2xxWU1oYpbic9YItxCyMoKlmVjGFbdv2hmW1EfF8mnJdsNGivi7N/ZzGTy/LJ+VDcDJDgdXEZXJI2nhq6aigDlJ73xq6kW+iaFC20jdJqkjgMcbTgQAkDkkcZ4wasBPEek24YSw6/GgLOjKttct1JCEYjY9lUhOMbnyCx6OigDirDwnf39ol34g1vVk1Kf8A0mS2trkLBaXBwVMWFyRGAFCklHwWdGZia0ZfC8lzamz1DXdXu7Bn3yRNIkTyDbjYZIlVthPzFQRk/LnZlD0lFAHKWGk67pEFnpGkTaZDotpiOCWRXeaKBVwkGzo2CFHmFwSoxjd89STf8JnAxkiPh++VCFEBWa2MwI+/5mZPLwTjZsfIXO4btq9PRQByceva5pMDDxJojTlP3j3mkESQCPPzFkdlkDKOSqhywGVySUXrKCMjB6VzNv4e1PSooIdB12RLWFPKjtNQt0uIYo+NoUrskJUAAFpG4znJwQAdNRWALHxI9xG02uaesKqQyQaYylj65aZsY9APzqMaT4hV1A8TBoowCm/T4zJI3P8ArWBCleeiKh4HPXIB0dFYEdh4kTywddsHVQAS2mnc/TJJEoHr0A61NNaa688hj1ayjhLZVRYEsox03GXB/KgDZorB/sbVmJZvE1+GJBCx21uEA9MGMn9aSDQ9URy03irVpBgDaILRR9f9Tn9aAN+isCbQ9Sc5j8VaxHwRgQ2h59eYKiOgauVcDxfq4YgbT9ns/lPf/ljzmgDpKK5/+wdQKIG8Va1uAGSI7QZIIOf9R3xj6H8a09Osp7VnM+p3l6G6CdYht+mxF/XNAF2iiigAooooAKKKKACs3xLpg1vw5qulNJ5YvrSW1L4zt3oVz+taVZl1r+lWl+tlc38EV0zpEI3bBLuQFX6ksAPqKAKnh7TtQi1PUtT1dbSO6u0hiEVrI0iKsYbncyqclnbjHAA5Nb1Z9lrWnX19NZ2l5FLcw7t8ann5W2tj1w3BxnB4ODWhQAUUUUAeZR/GDTRqN+t5o+qW2k2WsSaHNqreU0CXKsFwwD71U5HzbccjPfHYjxZoR241O3+bUTpI5PN2M5h/3uD+VefL8HriW41e0v8AxGJvDmp67Jr1xp8dgI5HkZ1YRGYyH5BtXOFBOOop03wrntteS9fxUsWjr4lHiFLGWyTP2hyQY/N3gncXwvHfGCcUAdrp3j3wtqN9eWlnrlnJNaJJLLltqhIzh2DHCsqnqQSB3rC0r4teG9S1nVIYbqNNI0+wjv31OVjHGQ7lAoVlB7DBGc7hisO0+CcAs4tNvtdmuNIsrK+sdNgS2Eclul198ySbj5pA4HyqPXNRz/Be41O11GLXvE32qS50610+KS208W/k/Z5PMjfHmMG5ABHGecY4wAdqfiT4PGlDUn161jszcG03SBkImC7vLKkBg2OcEZNW9H8b+G9ZSyfTNYtrgXscstuFJy6xHEhwRkbcjIODXG6R8JXsrvSrqfVrMz2WqJqbm204wifbE0e05lY5+bO4k9MYqunwfu7O8tb3SfFBs72G61CVpDp6yK0V2wZo9pfgrgYbv6UAdZqPxO8GabbWlxe+IbKKG7gFzAxLHzIi23cABnGc/ke1a3hrxZoXidr1fD+qW1+bJxHP5LZ2EjKn3BAOGGQcHBrzuD4L+VpCWP8Ab2dvhmXw5v8Asf8AflEnnY8ztjGz8d1df4N8F/8ACN+Ita1T7f8Aaf7StbG28rydnl/ZomTdncc7t2cYGMd6AOwooooAKKqalqdjpi27ajdwWwuZ0tofNcL5srnCouerE9AKXT9QstSso7zTry2u7OXISeCVZI3wdpwwODyCPrQBaoqnrGpW2kaZcX96xW3gTc20bmY9AqgcsxOAFHJJAHJp2k3yanpVlfxRyxR3UKTrHMu11DKGAYdiM8igC1RRRQAUUVDdXdvaLG13PFAskixIZXChnY4VRnqSSAB3NAE1FFFABRRRQAUVhJ4lt5PFLaLFDK5jBSW5BURxzbFkEOM7ixjbeSBgDbk5YCt2gAooooAKKKKACiiigAoozzjvRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRUN7dW9jZ3F3eTRwWtvG0sssjbVRFGWYnsAATmgCaiq8F9aT3MtvBcwS3ESJJJEkgZkR87GIHIDbWwe+046VYoAKKw9f8Tado1zHYyzI+rXFvLPaWW4K9zs2jYpPyhizooBIyTxnBxd0LU49X0iwvkXyjdW0Vz5LMGZA65AOCR6jI4ODigC/RRRQAUUUUAFFFFABWDqdhdal4n07zoyukWCm6zuH7+5OVQYznCDc3IxuZCOVNb1czr1/qOm6/pRW4B0+7uVgdGgHlxgqerg53lsBeNvODzg0AZnhbRtTtdX01buzeGDTIb2I3LSIwuTLMjIVAJbGEJbcBg4HPWuk1jQbTV5I3u5tSjaMbQLTUbi1BHuInUE+5rG8Palqn/CQz2WvPcwTSyXT2kLRReTLAkxCMrqS2QjRkhsH5jxxW9rGt6VokUcms6nY6fHIdqNd3CRBj6AsRmgDG8ERG1vfFFitxdzW9pqaxwfarmS4dFNpbOV3yMzY3OxwT3rV8T3k1loV1JaP5d3Jtt7Z9u4LNIwjjJHoHdc+2aw/A2p2F/e+MtQsb21ubBtVVhcwyq8RC2NqGO4HHBBB9MGuR8OJfzeJNJtbm5u7mx10r4j+zzN5gttrSOyqXyVUNJYjaDgMpIA3GgDc8MeLr641HwzZyXNnqVhdWEEVxfhfLmlvnt2uAQg+VUMUTsV6gyR44zUlh4bj8XaXJqut3WqMb/fNa25uWSO2j35tpERcbJVQK+77wZjknau23pvgSxuPA8nh3xXbWWpxzMRO0cbRiYJhIn67lcRJECQeCvBxiuyACgBQABwAO1AHN+CPE1rrljBam7SbWbawtLm/jVT+7M8e5TnGOdrHAPAx0yK3ory1lvJ7SK5he7gVHmhVwXjVs7Sy9QDtbGeuD6V5Lqnh+7sdP1bwjpupzWl7fpYQ2uoWp8ueGIyzhVBHzER29vzlvmO/G0HjPvtF8R69axanDb6jpGpeJGlttRNsj2zwG2+e2dj99Fb7PIu4n/l6xz8tAHqfjHWBpmkXUVpcRJrM8DLYxNglpWZIkbb3USSxAnoNwzXIX/wDaXgeO/wBG0Oz1G5TVYi2naiYjcJBqLqVY3JH3VeQRyb9u0tJKTjiqX9v6Z4j1KDXdPRZ/td9YaVZyBMs214buRVYDI2qZS4JwDAQeRivWqAOI8GfEjRPFOtvoli1z/atvame6SSExiGRHEcsJB53oxGRjGGUgnNduTgZPSuK+JEUGm2um+I4rEzXOj3UlwnkWxllZpYJIMAINxBaSMtgHhc9sjndC8RWUPwfudH0y8f8AtXRPC9qZWMRBjeW1Pk+oLHZnAJ6jmgDofC/xCsdXvrWyv4102+1ER3GmWzS+bJdWskUkkcpwuEJEM2VyQpUDdllB1J/GWjRz+IYorlbmTQbVbu/Fuyv5YPmnZweHAhYlTjGV9afquj2MMGjzR2lt9o02WGG0neNTJAjOiOqNjK7l+U4xkcGvJdGCCG302C3F9qPjCx027vFQIrss09zNeTyglcRrG2wHkjMSdxQB2vh0yeMtTUeJYbO5Gm6f9mvbNI99qb2R3SdSr5zsWIBc5+Wc9QwqPxt8P/DNrpc2uWelizudJZNUgjsiYohLA4l3+Sv7tnYLsLFSxX5cjjHfWWn2ljNey2kCRSXk32i4K/8ALSTYqbj77UUfhSaxZnUdIvrISeUbmB4RJt3bdykZx3xnpQBzthpFnr3iK/1jVIkvks7oQaakw3x25iA3Soh4Evm+YN/3sIoGBnPJeGtUure5b7FfXRttPsLjRLWylw0clzbTQwiVsAZYySbMjAwOnWvRfC+n3Ol6HbW1/cLc3xLzXMqjarSyOXfaOy7mIUHkDGSTzWTqngy0mutEl07bZLY6nLqM23cWnEheSRM5yA0xjc9vkAxjAoAzNI8WXllp94dXLag+naUZn8iHE9zPACLgheFyxaLaoAwSexAHX6DqkOtaLYanbJLHDeW8dwkcwCyIHUEKwBOGGcEZ4INcbb+CZb27sLm6WKxgg1O9u7u28sSSXgN0JLc+YrDYP3Fu5GCSFVDj5s53hnxLJp/jm70K4MMem6Zp9zJeTshUwOtyzQITnABt90mOpXB4oA9NuriK0tZrm5kWOCFDJI7HAVQMkn6AV5p4xu7TxRYXGrWlwz2GlaGmu2DovzGeQO8MwVhwyLAcAjkTMCKi1zx2NZ0HQ7H7MtpJ4jtGgmgebbLbztcQQPAMgZZRJck8Z/cMccHHUeFtGv47HxDa61DCkdxdyw2ixyb1NmECxDGBt+XIK885OeaAOridZI0dDlWAYfQ06sDwFqH9oeEdJeWaKS9SztxdpGeYpWhRyrDqpw6nB5wwPeue1LxtfaL4p1s6vBaf8ItZo8Uc0G5rpbiO1F06uvQqYt5UjBymD94GgDq/Emv2Xh60tbjUXYJc3kFjGFxlpJpFjXqRwN24/wCypPPSud8S+Io9W0650zQb25t76TV49FNxCoV1bCS3BjZgRlYfNw2OGU45FVfiN5viDTtOs9LVjLPZXmows6FcFbZo0znlTvuYz0yNtVfCmnXWo6zo+r6VdRy+HZLi/wBQkbywjmczTrGMg/MrJcvzj/lghz82KANK40Wz8NSeEUjkvLhYtWk8y6uH8yR3mgnG6Rsc5dkUH/dFdzXJfE9nj8NQTQRrLdRanYG3R3KK0rXcSIGIBIXcwyQCcZwD0rj1vf7T8XfDDUNaRn1m2TUrS4aFR5SXChYJmHOdplTavHRucUAeu1Al5bvfzWSTIbqGNJpIgfmVHLhWPsTG4H+6a4yL4jWcGh6jqWrWdxbJaaq+nLHHtkaZA2VnUZGE8o+a2cEKrnkAZ5XxZrFx4f1b4h61bXMsU1zaW1hau4JEEkZVPNA2t+7R71WPDfdbg9KAPZKKwG8TQr44/wCEaNrOJP7OOoG7JXygPM2eX1zv6t06D645Pwt8SrJvDekXWsXMtzdatrkumW4ihCsokld7fenylV8gwnJG7DKTyc0Aeh3d9aWbW63lzBbtcSiCESyBDLIQSEXPVsKTgc8GuB1ibW9d1zWLWyEt3ohnGg3VpG6RrGjxwyS3e/h9yrJLHtVjyEIHUjnvEOtzeJ9Z0g30UUFnpfiAXFp5QZjII5rSBGkJxjIvJWwOMBDk4OfQ/ACEaJdSusqvPqd/L+9OSVN1LsP02hce2KAPOtF8Stp2oaXqOpPJNb6LYyaFcuvztHcxQSz3WTjcQy2tucnJ6YAy2fQvhvNq8vhK3TxLeLe61DNPDdTrGsYZlmcDAUAYChQOOcZqj4t8DQappy2ejC202O51M3upbIyDdJJG0VwMgjDvG5G/t168jOHi2Sy+JkfhfTLWGW1N2X1S6Y7fs5mt3kgRRnLO7ROScFQAB1YYAPRqgv7u30+xuLy9mSC1t42mmlc4VEUZZifQAE1474Z8SXmleDJrxnlSfU/FVs8ZI3hILuWC5ZTycAQyuufUdq2vE/iY+LfhP4t/s+22SSyz6LGN+8OJHEKTDgcMkqyY7A9T1oA9NjdZI1dCGRgCCOhFOrP8PXaX+gaZeRf6u4tYpV+jICOv1rQBB6c0AFFNZ1UMWZQFGTk9B6muStfHdjeaV4c1O1t7hbDWNQOn7rlTC8DYlClkIzzJEqAcf6wHtigDf1vWLTRrJLq9ciJrmC1+XBIeaVIkz7bnUn0GTXDaz431HRtT8cXjwLd6ZpOnrLY2y/IZJYlLTkttzjMsS5GQNh4znPHeIbf+1rLVbKIzXeo3+uXupRJF94+Va3UMGO3D2iAe4U1euYX8/wAKwX2n3MM/iKe/H2O4jHmLFNfw3TJLz8rC3V8rzggjJxQBaa/1jUr7xBaW2r6hBdeIrhrXT/Lk+SyS3uJoJ3iyDsPlRo5Pd34I60sPibVtYtJruO7urez8R2cdtYkFVawffbQM6gfx+bdTEkk/6hccde20vwTZW3/CJXF7NLdan4dtnghuVJiWV5I1SV2QEj5tucZOCaiHgKwhufD72txOkWkXt1drG/zeYs7O5izxhVkaNl64EYHOc0AeLaTa6pq/h7VtWtpblxqFgl618QZXkl0mGNEBZgRua7y2MAMsT+pJ7bUHTVvGkNjdXk91Y+LbiaI2sku6CK305xlEA6eaS+7JwwfBAI59feGN4XhaNfKcEMuOCD1/nVLw7pFvoGg6fpNk0j29lAkCPKQXfaMbmIABY9ScDJJoA8U8X2niDRE09r+5s9M1fV7WebUbnTHfLGxVp7dFYhc/IoVhjJG/HGTXT6zqOpaprevaTbane2Y1ie3sdOlgk2NDFE0i3ckRwcSApICe2YumQa9F1bRdO1hrU6nax3P2V3kiD5wC8TxNkdCCkjgg5HPqBjlfBngeWw03wlP4ivpbzXtEiuA00MzeVLJP/rGYEAv7E47nFAGb4P0q38dQ23iXxAk000N3azW0Tfu1hmtoWRgVABylxLdAgk8qOwGY/CXhO58GeNtHzNf6ob7SpLK9vUh2QhoChgLoDsiAj3RqF6nJOSWavS7e3htozHbxRxIXaQrGoUFmYszYHcsSSe5JNS0AFFFFABRRRQAUUUUAFZc+gafcaouoTxzyXCOsqq9zKYg4GAwi3bNwHfbnv1rUqpq1/BpWlXuo3ZItrSF7iUgZIRFLH9AaAK9loVhZ6i9/CkzXTK6B5riSXYrMGZUDsQgJC8KAPlHoK06yNC1l9Rnu7W6s3sr21EbPCzq/yuCVII+jA+6nqMEu1jXrTSJI0u4dSkaQbgbTTri6AHuYkYA+xoAy/DcMVzq/jiC4jSWCXVESSORQyupsLQEEHggjtXU1y3geU3d74ovlt7yG3u9TWSH7VayW7Oos7ZC2yRVbG5GGcdjXU0AFFFFAGfc6Np1zrNlq1xZwyalZRyRW1wy5aJZMb9vpnaBnrjI6E50KKKAMrw14e0vw1olppGi2q29haFjDFktsLMzMQTk8lm/OtUUUUAFed3fwxs4b3RX0Of7JBayNFdiTMjzWnnLcLAGPZXjjRc5xGWA7V6JRQBm+JNHt/EGg3+k3rSJBeQtCzxHDpkcMp7MDgg+oFTWul2NrJbSQ2lus1tB9lhlEah0i+X5AcZC5VTgcfKPSrlFABRRRQAUUUUAFcx4q8IWmuRMsPk2Uk84kvZEgBa8jMTQvG5BBJMTsobOV+UjOMHp6KAMfTPD1lp2t6nqluZjPqBQujvmOPaD/AKtf4NxZmbHViSeSa2KKKAPFU0rXvAcaaPZQ6nqkFzcpqkt9bRyHctuzs8JKZKEwQ2cKocK53Dn5hXY+H9Es/E3hES6ijNDfao+rRP5YR5Ixcl4NwZcgNCsaMCAdjFTiu5ooA4rw3oer2njS/uLsBdFtVmj03N0ZWZJ/Idl2kZRUeFgoJPD4ACqBXW6fY2mm2UVnp1rBaWkI2xwQRiNEHoqjgD6VYooAbJGkqhZUV1DBgGGRkHIP1BAP4V55rHgXUJNS1y7025syrvbXukw3GQttdLOJp1JUZEcrxQsxBJy0hx6+i0UAeYaj8P8AV5baPTLe/tfsC6YsD3ZLJPLcraT2u5kAI2sJkfduyDHjBzkXdK8H3+r2WkXfibyraZvt7ajpXFxHJFdSeYsJk4+aMrCNy8HYwHBBHoVFAHh/xA0jxD4X+H19rNzqK3Gq2l3BCksId5Lm3aAWI3EbSrlpmnwNwVwB833q7LWvhjpt9cXV5Y3dxYamY4TZXKokn2KePyv3yqwIJYW9ujA9VjwMbmJ76igDjtG8AaZpmj3tis1yXv8AT4LG6ljkKbjHF5XnIMnZIV25IP8AyzT+7muk0XTYNH0iy020MhgtIUhRpG3OwUYyx7scZJ7nJq7RQAVm+IdGtde0ifT70zJHJgrLA5jlhcHKyRuOVdSAQexFaVFAHnGt+CdQ86+tNAWzttNktGntC0zIYL5bb7NECoU/uwgjIIOVKdDxUWh+Cdd0r7Bpcc2m/wBiebY3V5MsribzLeCNPLjj2bdrPBESxboXG3ODXplFAHk2k2fjHwBYrfT2MniKzFtbWk+nadeM7WkdvFt863jkVQ7Scloxg52gF8ZqHQdB+ImlaFp2j6ZJYWiq51N72e585nlYLJLZzp5ZIEk8kp82NiQqngEgH1+igDyy88LeKNYS98RG00zTPFcsrWaW81000TadtEbQGZEBAZg1wrBCVYqCPvCjxF4K17UtcvUtPsUWnWl3/bmlSSSnH27am2KRAufLEiSuzA5InwvIJr1OigDm/CXhe10fT9JlurW2bW7WxFpLdp8zNuIeQByAWUyAtyB1zgZNb09pbzzW809vFLNbuZIXdAzRMVKkqT0JVmGR2JHepqKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqlrenQ6xo1/plyWEF7byW0hXrtdSpx+Bq7RQBi6BpFzY3d7e6lex3l9diJGkig8lAkYIUbdzc5ZyTnv0GK2qKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigCpqmoW2l2T3d67pArKpKRtIxLMFUBVBJJLAcDvWZ/wlml/3NU/8FV1/wDG6PG6u2gExRTTGO7tJSkMbSPtW4jZiFUEnABPA7Vmf23b/wDPprH/AIKrr/43WFSpKMrI9HD4WFSlzuLbu1o/JeT7mn/wlml/3NU/8FV1/wDG6P8AhLNL/uap/wCCq6/+N1mf23b/APPprH/gquv/AI3R/bdv/wA+msf+Cq6/+N1HtpeX9fM1+pQ/59y+/wD+1NP/AISzS/7mqf8Agquv/jdH/CWaX/c1T/wVXX/xusz+27f/AJ9NY/8ABVdf/G6P7bt/+fTWP/BVdf8Axuj20vL+vmH1KH/PuX3/AP2pp/8ACWaX/c1T/wAFV1/8bqObxjpEEMks39pRxRqWd30y6CqBySSY+BVD+27f/n01j/wVXX/xus3xLqSXvh3VbW2stXeee0lijX+y7kbmZCAMmPHU0nWlbp/XzLp4GnKajKEkn5//AGp6HRRRXWeMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZniTXdN8NaJdavrd0lrp9soaSVgTjJwAAOSSSAAOSTXMf8LS8OxaJc6nqC6pp0cEkUQhvdPmhmmeTPliNCuXLbWxtz0OcVb+KvhKXxp4Pm0u0u0tL1Jorq2lkXcgkjcMA47qcY/HPOMVy/iXwl458VaXYXGq3Hhuz1zR9Rt9R05LUzSW7vGGDLMWAbDbhjaMjHU5oA6O2+JPh+SOxN0b/TpLy7eySHULKS3dZVQSEMHA2jawO48e/Wt3wt4h0/xTo8eq6O8sthKzLFK8TRiQKcblDAErkHB715j8QPhx4n+JGn6JbeKrjRrQW19LJONNll+W3aIIAjMvzPu3E5CjBA+vSeEvBeqL4Z0ax8WajMt7pA8iGTRdRuLaKeJcbDLGuwFsAAg7h155IoAs3PxR8M2+ry2Uk935MN2LCbUFtZDaRXJ48ppsbQ2SAewJ5Ip0nxQ8LxeJZNDnu7mK7jvF09pHtJRALhhlYzLt2Bj2BNcRf/CjX5tC1bwfFfaUPCOpap/aEly3mfbY4zKspiC42E7lAD7hx2rV0n4SrJ4413W/EV09xaT6vHqllZQTsIt6LhWmQqMsD0AJHrQB3HjLxXZeE7FLrULbUriNtxK2Nm9wyqoyzNtHyqB1JwKwdV+LfhLTrexnN5c3MN1ZDUt1rayS+TalgvnSADKLuOOecg8VN8W9H8W6/wCH10vwddabaJdFo7+S7leNzCRgpGyo+0tkgtjI7e3Ba18KPEk8JOkf8I9YG+8P/wDCP3dqJZjFbIJMrJC2zc52cEMF55yaAPa3v7RLOK7a6gW2lCmOVpAqNu+7gn1qAa7pB006gNUsDp6tsNz9oTyg2cY35xnPGM1yHjjwHLrfgXQfDlk9rLDp11ZNJ9sztlhgK7gQAckqOh455NeeeLPh7feGWl1OysLO9sx4mOqW2kW9pPPC0bW+z95HFExQgqSCFZQSOeaAPadd8T6Vo3hi91+5ukl020jaR5LciTdjjauDgsTgAZ6mq8Pi/TX8QXOjT+ba3dtYxX8xuAqIkcjFQC2fvAg5H615P4F8La9c+EvBeg6rpM1lYPqlzrOpKy7QiJM0kELKf77sjbT0Cc+la3xJ+F2ueJfHE/iDTL+wSJILPybK6ZvKupIJmcpOAh/d4bjBPIHHANAHqp1rSxfiyOpWQvTtIt/PXzDu+78uc89vWr9fNjeGNeHxOt7OLRDcRnxaNen1Q2k6tHFsOYjM8YR41zhdrknj5VOa+k6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5yW88WiVxFomgtGCdrNrMykjsSPspwfxNdHRQBxWpx+M7290idNK0GFbG6a4ZBrMx84GGWPYf9FGBmQN3+707jQ+2eMf+gF4f/8AB1N/8iV0tFAHNfbPGP8A0AvD/wD4Opv/AJEo+2eMf+gF4f8A/B1N/wDIldLRQBzX2zxj/wBALw//AODqb/5Eo+2eMf8AoBeH/wDwdTf/ACJXS0UAc19s8Y/9ALw//wCDqb/5Eo+2eMf+gF4f/wDB1N/8iV0tFAHNfbPGP/QC8P8A/g6m/wDkSj7Z4x/6AXh//wAHU3/yJXS0UAc19s8Y/wDQC8P/APg6m/8AkSj7Z4x/6AXh/wD8HU3/AMiV0tFAHNfbPGP/AEAvD/8A4Opv/kSj7Z4x/wCgF4f/APB1N/8AIldLRQBzX2zxj/0AvD//AIOpv/kSj7Z4x/6AXh//AMHU3/yJXS0UAc19s8Y/9ALw/wD+Dqb/AORKPtnjH/oBeH//AAdTf/IldLVPV5L6LTZ30m3guL4AeVFPKY0Y5GcsASOM9jQBy2ux+NNTso4I9K0G2ZLq3uC66zMSRFMkhT/j1HDBCv8AwLoelaH2zxj/ANALw/8A+Dqb/wCRK4zQviVrWo6QuqX+mabp1i2pJpquJ5Lhml80Iy7Qq4HXDZ+orcvPijoVtq0un/ZtXmmju5LDfBYu6NcIu7ylYdWI6AfU4HNAGv8AbPGP/QC8P/8Ag6m/+RKPtnjH/oBeH/8AwdTf/IlYl18W/DMGkadqCtezLewSXKwxwfvI442KOzgkYwwK4ySSOM1teIfFEFloGlarZXELWuoXFtHFI8bOHSYjBABBBIIwT070AL9s8Y/9ALw//wCDqb/5Eo+2eMf+gF4f/wDB1N/8iVnRfErQ5NeTSxFqQZ9Qk0v7S1owtxcoSPL8zoScHGPxxV3xj440zwpPBBfw39xcTQS3CR2duZTsjwXJxwAAc5NAEn2zxj/0AvD/AP4Opv8A5Eo+2eMf+gF4f/8AB1N/8iVz2ofFTSZNB1m80wzwS2FrDeI99ZyKksMrALIq8Mynpnj8RWhd/ErQ7XW20yWLUt0d8unS3K2jGCOdsbVZ+nOR/XFAGj9s8Y/9ALw//wCDqb/5Eo+2eMf+gF4f/wDB1N/8iVXPj/Rfs8Eyfa5BPfy6bGiQks08YYsoH/ATj1rD0X4t6Zd+ENM1rUdPvrObUJGigs0XzGlZcklGIUMoA5Y4APHWgDpPtnjH/oBeH/8AwdTf/IlH2zxj/wBALw//AODqb/5ErFj+LHhu4k06PTxf3st9ALhI7e3yyIXMfzAkc7lYYXJ4+ld/QBzX2zxj/wBALw//AODqb/5Eo+2eMf8AoBeH/wDwdTf/ACJXS0UAc19s8Y/9ALw//wCDqb/5Eo+2eMf+gF4f/wDB1N/8iV0tFAHNfbPGP/QC8P8A/g6m/wDkSj7Z4x/6AXh//wAHU3/yJXS0UAcVrsfjTU7KOCPStBtmS6t7guuszEkRTJIU/wCPUcMEK/8AAuh6VofbPGP/AEAvD/8A4Opv/kSulooA5r7Z4x/6AXh//wAHU3/yJR9s8Y/9ALw//wCDqb/5ErpaKAOa+2eMf+gF4f8A/B1N/wDIlH2zxj/0AvD/AP4Opv8A5ErpaKAOa+2eMf8AoBeH/wDwdTf/ACJR9s8Y/wDQC8P/APg6m/8AkSulooA5r7Z4x/6AXh//AMHU3/yJR9s8Y/8AQC8P/wDg6m/+RK6WigDmvtnjH/oBeH//AAdTf/IlTWd14pe6iW80bRIrYsBI8WrSyOq9yFNsoJ9sj61v0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcXB8OdIg8Px6Olzfm2TUxqoYum/zRJ5m3O3G3PbGcd6fF8PtKjv1u1uL7zBrL65gumPPePYV+79zA6dc967GigDzwfCXQ47LTIba71K3n09Jo47pGiaRkllaVkYNGUIDMcfLketdFq3hOy1TQtM0q5nuhBp8tvNG6su9mhIK7iVwc45wB+FdDRQBxy/D7Sl8vFxffJrreIR86f8fDbsr93/V/MeOvvV7xF4QsNf1OG+vJrpJYrK4sQImULsnUBzyp+YY47eoNdHRQBwN38K9EutMnsZLrUhDNpVtpDFZE3CGBgyMPk++SOT09AKu3Xw+0q5+3b7i+H2zVYtXkw6cTR7cKPl+58oyOT712NFAHB23ww0m21yHUotQ1gLDqL6pFZm4U26TODuwpXODknrn361Enwo0VNDsNLW+1XytOneexlaSNntQ2d0a5TayHJ4cMfevQaKAPO9T+E2i6rBZQalf6pc29qAPLcw/P+8Lk5EYZCScHyynAAr0SiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Example of a paradoxical basal sphincter of Oddi (SO) pressure elevation following the intravenous administration of cholecystokinin-octapeptide (20 ng/kg). Normally, CCK reduces SO basal pressure. This finding suggests possible denervation of the sphincteric zone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Walter J Hogan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_19_19761=[""].join("\n");
var outline_f19_19_19761=null;
var title_f19_19_19762="Membranous VSD subcostal coronal 2D";
var content_f19_19_19762=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/58967/Membr_VSD_subcost_movie.mp4?title=Membranous+VSD+subcostal+coronal+2D\" style=\"width:496px;height:384px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Membranous VSD subcostal coronal 2D",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subcostal coronal movie clip showing the membranous ventricular septal defect (VSD) and adjacent structures. The atrioventricular valves can be seen in motion in their respective ventricles.",
"    <div class=\"footnotes\">",
"     AO: aorta; LV: left ventricle; RV: right ventricle; LA: left atrium; RA: right atrium; IVS: intact trabecular portion of the intraventricular septum; arrow: VSD.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_19_19762=[""].join("\n");
var outline_f19_19_19762=null;
var title_f19_19_19763="Frenulotomy";
var content_f19_19_19763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52382&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Frenulotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tongue is elevated with two gloved fingers to expose the lingual frenulum. The frenulum is divided close to the underside of the tongue to avoid injury to the submandibular ducts (arrows) and lingual nerves.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_19_19763=[""].join("\n");
var outline_f19_19_19763=null;
var title_f19_19_19764="Urinary incontinence treatments for women";
var content_f19_19_19764=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Urinary incontinence treatments for women (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?19/19/19764/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/19/19764/contributors\" id=\"au4227\">",
"       Catherine E DuBeau, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?19/19/19764/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/19/19764/contributors\" id=\"se1605\">",
"       Kenneth E Schmader, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?19/19/19764/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/19/19764/contributors\" id=\"de8761\">",
"       Fenny H Lin, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?19/19/19764?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      URINARY INCONTINENCE OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Leaking urine is never a normal or expected part of aging, and you should not just \"learn to live with it\". In most cases, treatments are available to reduce or eliminate leaking. Your healthcare provider can help you with treatment if you are bothered by leaking urine, having to rush to the toilet frequently or getting up from sleeping to go to the toilet.",
"    </p>",
"    <p>",
"     This article discusses treatments for the two main types of leakage in women, urge and stress incontinence. Information about the different types of urinary incontinence and the causes, symptoms, and diagnosis of urinary incontinence is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/16/9474?source=see_link\">",
"      \"Patient information: Urinary incontinence in women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     More detailed information about incontinence is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"      \"Clinical presentation and diagnosis of urinary incontinence\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"      \"Treatment of urinary incontinence\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      TREATMENTS FOR STRESS AND URGE INCONTINENCE",
"     </span>",
"    </p>",
"    <p>",
"     The following treatments may be helpful for women with stress",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     urge incontinence.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Fluid management",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you drink large amounts of fluids, you may find that cutting back on fluids will reduce your leakage. Between 32 and 64 ounces of fluid per day (from both food and fluids) is sufficient for most people; you may need more fluid when you are active and sweating or if it is hot.",
"    </p>",
"    <p>",
"     One recommendation is to drink a small amount of fluid at regular intervals throughout the day (rather than drinking larger amounts all at once). If you get up frequently during the night to urinate, stop drinking fluids 3 to 4 hours before you go to bed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Treat other health conditions",
"     </span>",
"     &nbsp;&mdash;&nbsp;Certain health conditions can worsen urine leakage. Treating these conditions may help to reduce or eliminate your leakage.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Avoid taking diuretics at a time when it will be difficult to get to the bathroom for several hours.",
"      </li>",
"      <li>",
"       If you have swelling in your feet, elevate your feet for several hours in the afternoon or evening and consider wearing compression stockings. Your healthcare provider may suggest that you take a diuretic (fluid pill) in the afternoon. These measures can help reduce nighttime trips to the toilet.",
"      </li>",
"      <li>",
"       Ask your healthcare provider if any of your medications (prescription and non-prescription) could be causing or worsening your leakage.",
"      </li>",
"      <li>",
"       If you have diabetes and your blood sugar levels are high, talk with your healthcare provider. Having high blood sugar causes your kidneys to produce more urine.",
"      </li>",
"      <li>",
"       In people who are obese or overweight, losing weight can help to reduce urine leakage.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      TREATMENTS FOR URGE INCONTINENCE AND OVERACTIVE BLADDER",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Bladder irritants",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some people find that certain foods and drinks cause them to go to the bathroom more frequently. This includes drinks with caffeine (including soda), alcohol, spicy foods, and acidic foods or beverages, and artificial sweeteners. It is reasonable to see if temporarily eliminating one or more of these items reduces your need to go urgently and frequently.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Bladder training",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bladder training can help you learn to go to the bathroom less frequently by \"retraining\" your bladder to hold more urine (",
"     <a class=\"graphic graphic_table graphicRef66056 \" href=\"UTD.htm?34/6/34923\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Bladder training has two components: going to the bathroom on a schedule while you are awake and using strategies to control sudden urges.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       You begin by going to the bathroom at specific intervals during the day, starting with a small time interval. For example, if you currently go to the bathroom every 30 to 45 minutes, you would start by going every 45 minutes, whether you feel the need to go or not. Many people can start by going every 1 to 2 hours.",
"      </li>",
"      <li>",
"       If you have an urgent need to go sooner, try to suppress the urge by standing or sitting still, performing a pelvic muscle exercise, and think of the urge as a wave that is fading away.",
"      </li>",
"      <li>",
"       After one to two weeks, you can increase the time between bathroom trips by 15 to 30 minutes.",
"      </li>",
"      <li>",
"       Your goal is to slowly increase this time up to a more normal interval. It is normal to urinate approximately every three to four hours during the day and for older adults to wake from sleeping up to once per night.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     For people with dementia or memory impairment, a different approach is used, called prompted voiding. This involves reminding the person to use the toilet regularly (usually every two to three hours).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Prevent constipation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Constipation can worsen frequency and urgency. Increasing the amount of fiber in your diet to between 20 and 30 grams per day can prevent constipation. Treatment of constipation is discussed in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"      \"Patient information: Constipation in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;In some people, urge incontinence is severe and a medicine is needed to get symptoms under control. Examples of these medications include oxybutynin (Ditropan&reg;), tolterodine (Detrol&reg;), fesoterodine (Toviaz&reg;), trospium (Sanctura&reg;), solifenacin (VESIcare&reg;) and darifenacin (Enablex&reg;). These medications may work best when combined with bladder training.",
"    </p>",
"    <p>",
"     If you do not respond to one medicine, you may respond to another. Some people take medicine temporarily, until symptoms improve, while others take medication indefinitely.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The most common side effects of these medications are dry mouth, constipation, and heartburn.",
"      </li>",
"      <li>",
"       If you take one of these medications for long periods of time you need to brush your teeth regularly and see a dentist every 6 months because dry mouth can increase the risk of cavities.",
"      </li>",
"      <li>",
"       There is a small risk of urinary retention (not emptying the bladder completely) with these medications, especially in older people.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Botox&reg;",
"     </span>",
"     &nbsp;&mdash;&nbsp;Botulinum toxin A, also known as Botox&reg;, is a toxin produced by a bacteria that temporarily paralyzes muscles. Studies have examined using injections of Botox&reg; into the bladder as a treatment for severe urge incontinence, with most studies reporting a decrease in the frequency of leakage [",
"     <a class=\"abstract\" href=\"UTD.htm?19/19/19764/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     There is a risk that Botox&reg; will prevent the bladder from emptying. If this happened, you would need to insert a catheter (a thin tube) into your bladder several times per day to empty. However, the effects of Botox&reg; are temporary, on average lasting only three to six months.",
"    </p>",
"    <p>",
"     The role of Botox in the treatment of urinary incontinence is not yet clear. The treatment holds promise for people with severe symptoms who have not responded to other treatments. Botox is not approved for the treatment or urinary incontinence. Further trials are needed to determine the best dose and if Botox is safe for people with less severe symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Electric stimulation",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are several types of electric stimulation available to treat urge incontinence, including an office-based procedure and a surgically implanted device.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Office treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Office electrical stimulation involves placing a hair-thin needle into a nerve near the ankle. This nerve is connected to nerves in the lower back that affect your bladder. The needle is connected to a small device that sends electrical pulses to the nerve. The treatment is not painful. It may help to reduce the need to frequently rush to the bathroom. This treatment is performed in a healthcare provider's office one to three times per week for six to eight weeks.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Surgically implanted stimulator",
"     </span>",
"     &nbsp;&mdash;&nbsp;A sacral nerve stimulator (SNS) is a device, about the size of a pacemaker, which can be surgically implanted. The device is placed under the skin in the upper buttock, and is connected with wires to a nerve (the sacral nerve) in the lower back.",
"    </p>",
"    <p>",
"     The device sends electrical pulses to the sacral nerve, which seems to help people with severe symptoms of urge incontinence, urgency and frequency, or urinary retention who have not improved with more conservative treatments. It is not clear how the treatment works, although studies show good results in most patients.",
"    </p>",
"    <p>",
"     Potential risks of the surgery include pain at the site where the unit is implanted (in the buttocks), movement of the device over time, infection, and others. More detailed information about sacral nerve stimulation is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/22/17764?source=see_link&amp;anchor=H17#H17\">",
"      \"Patient information: Treatment of interstitial cystitis/bladder pain syndrome (Beyond the Basics)\", section on 'Electrical stimulation for painful bladder'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      TREATMENTS FOR STRESS INCONTINENCE",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Pelvic muscle exercises",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pelvic muscle exercises, also known as pelvic floor muscle exercises or Kegel exercises, strengthen the muscles involved in controlling urine leakage. This is explained in a table (",
"     <a class=\"graphic graphic_table graphicRef81507 \" href=\"UTD.htm?16/7/16507\">",
"      table 2",
"     </a>",
"     ). (see",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/0/19456?source=see_link\">",
"      \"Patient information: Pelvic floor muscle exercises (Beyond the Basics)\"",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Practicing these exercises on a regular basis may help to reduce urine leakage caused by stress incontinence.",
"      </li>",
"      <li>",
"       If you have sudden urges to urinate, you can perform these exercises to help temporarily control the urge.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Vaginal pessaries",
"     </span>",
"     &nbsp;&mdash;&nbsp;A vaginal pessary is a flexible device made of silicone that can be worn in the vagina. A pessary can help to reduce or eliminate stress incontinence. A pessary is a reasonable treatment if you want to delay or avoid surgery. When fit properly, you will not feel the pessary.",
"    </p>",
"    <p>",
"     The pessary must be removed and cleaned with soap and water periodically. In addition, there is a small risk that the pessary can cause irritation inside the vagina. Most women who use a pessary see their healthcare provider every three to six months for an examination. Some women, especially those who are sexually active, are able to learn how to insert and remove the pessary on their own.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Surgical treatments",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgery offers the highest cure rate of any treatment for stress urinary incontinence, even in elderly women. There are several surgical procedures for the treatment of stress incontinence. Each procedure has its own risks, benefits, complications, and chance of failure. These issues should be discussed in detail with a surgeon who is experienced in performing procedures to treat incontinence. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link\">",
"      \"Stress urinary incontinence in women: Choosing a primary surgical procedure\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In general, surgery is not recommended until you are finished having children because pregnancy and childbirth can cause damage, potentially allowing leakage to recur.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      OTHER MEASURES",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Pads",
"     </span>",
"     &nbsp;&mdash;&nbsp;While pads are not a recommended treatment for incontinence, they are necessary in some cases. Pads and protective undergarments are available in a variety of sizes and absorbencies, depending upon how much you leak. Pads designed for menstrual bleeding are usually not recommended.",
"    </p>",
"    <p>",
"     Information on pad varieties and other urinary incontinence supplies is available from medical supply companies and urinary incontinence advocacy groups (see",
"     <a class=\"local\" href=\"#H22\">",
"      'Where to get more information'",
"     </a>",
"     below). The US National Association for Continence has an online tool that can help you to choose a protective garment (",
"     <a class=\"external\" href=\"file://nafc.org/\">",
"      file://nafc.org",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Whatever pad you choose, it is important to keep your skin dry and to control urine odor. If your skin is exposed to urine for long periods, it can become irritated and can potentially develop skin burns or infection. Protective products for the bed or other furniture may also be needed.",
"    </p>",
"    <p>",
"     Pads are expensive and are not usually covered by insurance; in the United States, some state Medicaid plans cover the cost of pads for people with very limited incomes. In other countries, pads may be obtained for no or little cost through continence advisor nurses.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Catheters",
"     </span>",
"     &nbsp;&mdash;&nbsp;A catheter may be necessary if you cannot empty your bladder completely or at all. Because catheters increase the risk of urinary tract infections and other serious complications, especially when left in place for long periods, they are usually a treatment of last resort.",
"    </p>",
"    <p>",
"     A catheter may be inserted and left in the bladder, or may be inserted intermittently to drain the bladder, and then removed. A healthcare provider can teach you or a family member how to perform intermittent catheterization at home.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Portable toilet",
"     </span>",
"     &nbsp;&mdash;&nbsp;If you have difficulty walking, talk to your healthcare provider. You may benefit from a portable toilet that can be placed close to your bed or living area. In addition, move electrical cords, throw rugs, or furniture out of hallways and walkways so that you do not trip or fall on the way to the bathroom.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H221\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3356981\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/8/22658?source=see_link\">",
"      Patient information: Urinary incontinence (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/60/11202?source=see_link\">",
"      Patient information: Pelvic muscle (Kegel) exercises (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/9/35987?source=see_link\">",
"      Patient information: Urinary incontinence in men (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/0/16386?source=see_link\">",
"      Patient information: Neurogenic bladder in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/56/35714?source=see_link\">",
"      Patient information: Surgery to treat stress urinary incontinence in women (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/36/43586?source=see_link\">",
"      Patient information: Treatments for urge incontinence in women (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3357008\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/16/9474?source=see_link\">",
"      Patient information: Urinary incontinence in women (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/0/19456?source=see_link\">",
"      Patient information: Pelvic floor muscle exercises (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/10/34977?source=see_link\">",
"      Patient information: Constipation in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/22/17764?source=see_link\">",
"      Patient information: Treatment of interstitial cystitis/bladder pain syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29929?source=see_link\">",
"      Clinical presentation and diagnosis of urinary incontinence",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/1/7192?source=see_link\">",
"      Epidemiology, risk factors, and pathogenesis of urinary incontinence",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11290?source=see_link\">",
"      Lower urinary tract symptoms in men",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=see_link\">",
"      Pelvic floor disorders associated with pregnancy and childbirth",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1546?source=see_link\">",
"      Pelvic organ prolapse and stress urinary incontinence in women: Combined surgical treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44409?source=see_link\">",
"      Stress urinary incontinence in women: Persistent/recurrent symptoms after surgical treatment",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32842?source=see_link\">",
"      Treatment of urinary incontinence",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/7/17530?source=see_link\">",
"      Vaginal pessary treatment of prolapse and incontinence",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43177?source=see_link\">",
"      Stress urinary incontinence in women: Choosing a primary surgical procedure",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16055?source=see_link\">",
"      Stress urinary incontinence in women: Choosing a type of midurethral sling",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33562?source=see_link\">",
"      Stress urinary incontinence in women: Retropubic midurethral slings",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/39/33401?source=see_link\">",
"      Stress urinary incontinence in women: Transobturator midurethral slings",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute on Aging",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nia.nih.gov/\">",
"      www.nia.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Urogynecology Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://augs.org/\">",
"      file://augs.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Association for Continence",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;1-800-BLADDER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nafc.org/\">",
"      www.nafc.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Simon Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.simonfoundation.org/\">",
"      www.simonfoundation.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes &amp; Digestive &amp; Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Urological Association Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.urologyhealth.org/\">",
"      www.urologyhealth.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       For continence resources in other countries, go to Continence Worldwide",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.continenceworldwide.com/\">",
"      www.continenceworldwide.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?19/19/19764/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 5, 2010.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?19/19/19764?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19764/abstract/1\">",
"      Schurch B, de S&egrave;ze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005; 174:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19764/abstract/2\">",
"      Janknegt RA, Hassouna MM, Siegel SW, et al. Long-term effectiveness of sacral nerve stimulation for refractory urge incontinence. Eur Urol 2001; 39:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19764/abstract/3\">",
"      Hassouna MM, Siegel SW, N&yuml;eholt AA, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol 2000; 163:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19764/abstract/4\">",
"      Burgio KL, Goode PS, Locher JL, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA 2002; 288:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19764/abstract/5\">",
"      Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003; 326:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19764/abstract/6\">",
"      Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women. Cochrane Database Syst Rev 2003; :CD001405.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f19_19_19764=[""].join("\n");
var outline_f19_19_19764=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           URINARY INCONTINENCE OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           TREATMENTS FOR STRESS AND URGE INCONTINENCE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           TREATMENTS FOR URGE INCONTINENCE AND OVERACTIVE BLADDER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           TREATMENTS FOR STRESS INCONTINENCE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           OTHER MEASURES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?34/6/34923\" title=\"table 1\">",
"           Bladder retraining PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?16/7/16507\" title=\"table 2\">",
"           Pelvic muscle exercises PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f19_19_19765="Transbronchial needle";
var content_f19_19_19765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transbronchial needle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 19G transbronchial histology needle extending from its sheath.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_19_19765=[""].join("\n");
var outline_f19_19_19765=null;
var title_f19_19_19766="Pioglitazone and metformin: Patient drug information";
var content_f19_19_19766=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pioglitazone and metformin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25479?source=see_link\">",
"     see \"Pioglitazone and metformin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1615054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Actoplus Met&reg;;",
"     </li>",
"     <li>",
"      Actoplus Met&reg; XR",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3890293",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause your body to keep extra fluid which can cause or make heart failure worse. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A small number of people may have more acid in their blood. Metformin may cause this. It may happen in people whose liver or kidneys do not work the right way.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700974",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give to a child. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702483",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to metformin, pioglitazone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703187",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Acidic blood problem, drink too much alcohol, fluid loss, kidney disease, liver disease, or very weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having an x-ray with dye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697351",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bladder cancer, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697808",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stop this drug for 2 days after you have an x-ray with dye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697748",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you are having surgery, if you have had a heart attack, bad infection, or stroke, or if you are 80 years of age or older and have not had your kidney function tested.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697216",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have eye problems from high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a chance of pregnancy in women of childbearing age who have not been ovulating.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698129",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Heart failure may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Too much acid in the blood (lactic acidosis) may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3890302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bladder cancer may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698656",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling cold.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699084",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight or in the way you see color.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695325",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting tablet: Swallow it whole. Do not chew, break, or crush it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11431 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-91.202.164.29-FFA7B79098-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_19_19766=[""].join("\n");
var outline_f19_19_19766=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1615054\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028040\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028042\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028041\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028046\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028047\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028049\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028044\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028045\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028050\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028051\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/56/25479?source=related_link\">",
"      Pioglitazone and metformin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_19_19767="Benazepril and hydrochlorothiazide: Drug information";
var content_f19_19_19767=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Benazepril and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/14/20710?source=see_link\">",
"    see \"Benazepril and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F139518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lotensin HCT&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F139531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin-Converting Enzyme (ACE) Inhibitor;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F139519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Not for initial therapy; dose should be individualized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Range: Benazepril: 5-20 mg; Hydrochlorothiazide: 6.25-25 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Add-on therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Patients not adequately controlled on benazepril monotherapy: Initiate benazepril 10-20 mg/hydrochlorothiazide 12.5 mg; titrate to effect at 2- to 3-week intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Patients controlled on hydrochlorothiazide 25 mg/day but experience significant potassium loss with this regimen: Initiate benazepril 5 mg/hydrochlorothiazide 6.25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Replacement therapy: Substitute for the individually titrated components",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F139520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose is individualized.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F139521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Not recommended; loop diuretics are preferred.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F139510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: 5/6.25: Benazepril hydrochloride 5 mg and hydrochlorothiazide 6.25 mg; 10/12.5: Benazepril hydrochloride 10 mg and hydrochlorothiazide 12.5 mg; 20/12.5: Benazepril hydrochloride 20 mg and hydrochlorothiazide 12.5 mg; 20/25: Benazepril hydrochloride 20 mg and hydrochlorothiazide 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lotensin HCT&reg; 10/12.5: Benazepril hydrochloride 10 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lotensin HCT&reg; 20/12.5: Benazepril hydrochloride 20 mg and hydrochlorothiazide 12.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lotensin HCT&reg; 20/25: Benazepril hydrochloride 20 mg and hydrochlorothiazide 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F139500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F139512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F139529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2563533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to benazepril, any other ACE inhibitor, hydrochlorothiazide, sulfonamide-derived drugs, or any component of the formulation; patients with a history of angioedema (with or without prior ACE inhibitor therapy); concomitant use with aliskiren in patients with diabetes mellitus; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2529313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: Any time during treatment (especially following first dose) angioedema may occur rarely with ACE inhibitors; it may involve the head and neck (potentially compromising airway) or the intestine (presenting with abdominal pain). African-Americans and patients with idiopathic or hereditary angioedema or previous angioedema associated with ACE inhibitor therapy may be at an increased risk. Prolonged frequent monitoring may be required especially if tongue, glottis, or larynx are involved as they are associated with airway obstruction. Patients with a history of airway surgery may have a higher risk of airway obstruction. Aggressive early and appropriate management is critical. Contraindicated in patients with history of angioedema with or without  prior ACE inhibitor therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestatic jaundice: A rare toxicity associated with ACE inhibitors includes cholestatic jaundice, which may progress to fulminant hepatic necrosis; discontinue if marked elevation of hepatic transaminases or jaundice occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: An ACE inhibitor cough is a dry, hacking, nonproductive one that usually occurs within the first few months of treatment and should generally resolve within 1-4 weeks after discontinuation of the ACE inhibitor. Other causes of cough should be considered (eg, pulmonary congestion in patients with heart failure) and excluded prior to discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hyperkalemia may occur with ACE inhibitors; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Thiazide diuretics may cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Anaphylactic/anaphylactoid reactions can occur with ACE inhibitors. Severe anaphylactoid reactions may be seen during hemodialysis (eg, CVVHD) with high-flux dialysis membranes (eg, AN69), and rarely, during low density lipoprotein apheresis with dextran sulfate cellulose. Rare cases of anaphylactoid reactions have been reported in patients undergoing sensitization treatment with hymenoptera (bee, wasp) venom while receiving ACE inhibitors. Hypersensitivity reactions may also occur with hydrochlorothiazide; risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can occur with ACE inhibitors (usually with the first several doses); effects are most often observed in volume-depleted patients; correct volume depletion prior to initiation; close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Although dose reduction may be necessary, hypotension is not a reason for discontinuation of future ACE inhibitor use especially in patients with heart failure where a reduction in systolic blood pressure is a desirable observation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia/agranulocytosis: Another ACE Inhibitor, captopril, has been associated with rare cases of agranulocytosis, neutropenia, or leukopenia with myeloid hypoplasia. Patients with renal impairment are at high risk of developing neutropenia. Patients with both renal impairment and collagen vascular disease (eg, systemic lupus erythematosus) are at an even higher risk of developing neutropenia. Periodically monitor CBC with differential in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic stenosis: Use with caution in patients with severe aortic stenosis; may reduce coronary perfusion resulting in ischemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Initiation of therapy in patients with ischemic heart disease or cerebrovascular disease warrants close observation due to the potential consequences posed by falling blood pressure (eg, MI, stroke). Fluid replacement, if needed, may restore blood pressure; therapy may then be resumed. Discontinue therapy in patients whose hypotension recurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Collagen vascular disease: Use benazepril with caution in patients with collagen vascular disease especially with concomitant renal impairment; may be at increased risk for hematologic toxicity. Hydrochlorothiazide can cause systemic lupus erythematosus (SLE) exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control. Use benazepril with caution in patients with diabetes receiving insulin or oral antidiabetic agents; may be at increased risk for episodes of hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with severe hepatic impairment; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM) with outflow tract obstruction: Use with caution in patients with HCM and outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria; acute porphyritic attacks have occurred with hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use benazepril with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use ACE inhibitors with caution in pre-existing renal insufficiency; dosage adjustment may be needed. Avoid rapid dosage escalation which may lead to further renal impairment. Avoid hydrochlorothiazide in severe renal disease (ineffective). Contraindicated in anuric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin receptor blockers (ARBs) and renin inhibitors: Concomitant use of an ARB or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgery: Use with caution before, during, or immediately after major surgery. Cardiopulmonary bypass, intraoperative blood loss or vasodilating anesthesia increases endogenous renin release. Use of ACE inhibitors perioperatively will blunt angiotensin II formation and may result in hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F139506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of ACE Inhibitors. Aliskiren may enhance the hypotensive effect of ACE Inhibitors. Aliskiren may enhance the nephrotoxic effect of ACE Inhibitors. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: ACE Inhibitors may enhance the potential for allergic or hypersensitivity reactions to Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of ACE Inhibitors. Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprotinin: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AzaTHIOprine: ACE Inhibitors may enhance the myelosuppressive effect of AzaTHIOprine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of ACE Inhibitors. Canagliflozin may enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): ACE Inhibitors may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DPP-IV Inhibitors: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: May enhance the adverse/toxic effect of ACE Inhibitors. Specifically, the risk of angioedema may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ferric Gluconate: ACE Inhibitors may enhance the adverse/toxic effect of Ferric Gluconate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gold Sodium Thiomalate: ACE Inhibitors may enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydrochlorothiazide: May enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Icatibant: May diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Dextran Complex: ACE Inhibitors may enhance the adverse/toxic effect of Iron Dextran Complex. Specifically, patients receiving an ACE inhibitor may be at an increased risk for anaphylactic-type reactions.  Management: Follow iron dextran recommendations closely regarding both having resuscitation equipment and trained personnel on-hand prior to iron dextran administration and the use of a test dose prior to the first therapeutic dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of ACE Inhibitors. Management: Administer angiotensin-converting enzyme inhibitors at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: ACE Inhibitors may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an ACE inhibitor.  Monitor patient response to lithium closely following addition or discontinuation of concurrent ACE inhibitor treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Loop Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: ACE Inhibitors may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May diminish the antihypertensive effect of ACE Inhibitors. They may also diminish other beneficial pharmacodynamic effects desired for the treatment of CHF.  The effects are likely dose-related.  100 mg doses aspirin appear to cause no problems, whereas 300 mg doses appear to significantly affect ACE Inhibitor efficacy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: ACE Inhibitors may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: May enhance the hypotensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F139507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F139516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F139523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F1623907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F139515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Benazepril-Hydrochlorothiazide Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-6.25 mg (100): $100.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-12.5 mg (100): $100.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-12.5 mg (100): $100.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-25 mg (100): $100.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Lotensin HCT Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-12.5 mg (100): $229.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-12.5 mg (100): $229.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-25 mg (100): $229.97",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6179739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; BUN, serum creatinine, and electrolytes; if patient has collagen vascular disease and/or renal impairment, periodically monitor CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cibacen HCT (PT);",
"     </li>",
"     <li>",
"      Cibadrex (AE, AT, BB, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CL, CY, DE, EG, ET, FR, GH, GM, GN, GR, GY, IL, IQ, IR, IT, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, NZ, OM, PR, QA, SA, SC, SD, SL, SN, SR, SY, TN, TR, TT, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Lotensin H (BR);",
"     </li>",
"     <li>",
"      Lotensin HCT (HN, PL);",
"     </li>",
"     <li>",
"      Zaprace-D (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9839999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Benazepril is a competitive inhibitor of angiotensin-converting enzyme (ACE); prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This results in lower levels of angiotensin II which causes an increase in plasma renin activity and a reduction in aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal tubules causing increased excretion of sodium and water as well as potassium and hydrogen ions.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F139514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3): 776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19767/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8650 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.172.26-E56BECDC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_19_19767=[""].join("\n");
var outline_f19_19_19767=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708648\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139518\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139531\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139519\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139520\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139521\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673292\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139510\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139500\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139512\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139529\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2563533\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2529313\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298825\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139506\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139507\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139516\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139523\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1623907\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139515\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6179739\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539823\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9839999\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139514\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8650\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8650|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/14/20710?source=related_link\">",
"      Benazepril and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_19_19768="Gabapentin: Drug information";
var content_f19_19_19768=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gabapentin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/8/2182?source=see_link\">",
"    see \"Gabapentin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/23/35191?source=see_link\">",
"    see \"Gabapentin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F175023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gralise&trade;;",
"     </li>",
"     <li>",
"      Neurontin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F175024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Gabapentin&reg;;",
"     </li>",
"     <li>",
"      Auro-Gabapentin;",
"     </li>",
"     <li>",
"      CO Gabapentin;",
"     </li>",
"     <li>",
"      Dom-Gabapentin;",
"     </li>",
"     <li>",
"      GD-Gabapentin;",
"     </li>",
"     <li>",
"      JAMP-Gabapentin;",
"     </li>",
"     <li>",
"      Mylan-Gabapentin;",
"     </li>",
"     <li>",
"      Neurontin&reg;;",
"     </li>",
"     <li>",
"      PHL-Gabapentin;",
"     </li>",
"     <li>",
"      PMS-Gabapentin;",
"     </li>",
"     <li>",
"      PRO-Gabapentin;",
"     </li>",
"     <li>",
"      RAN&trade;-Gabapentin;",
"     </li>",
"     <li>",
"      ratio-Gabapentin;",
"     </li>",
"     <li>",
"      Riva-Gabapentin;",
"     </li>",
"     <li>",
"      Teva-Gabapentin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F175060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Miscellaneous;",
"     </li>",
"     <li>",
"      GABA Analog",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F175027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anticonvulsant:",
"     </b>",
"     Oral: Immediate release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Initial:",
"     </i>",
"     300 mg 3 times/day, if necessary the dose may be increased up to 1800 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance:",
"     </i>",
"     900-1800 mg/day administered in 3 divided doses; doses of up to 2400 mg/day have been tolerated in long-term clinical studies; up to 3600 mg/day has been tolerated in short-term studies",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If gabapentin is discontinued or if another anticonvulsant is added to therapy, it should be done slowly over a minimum of 1 week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Diabetic neuropathy (unlabeled use):",
"     </b>",
"     Oral: Immediate release: 900-3600 mg/day (Bril, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neuropathic pain (unlabeled use):",
"     </b>",
"     Oral: Immediate release: 300-3600 mg/day (Attal, 2010; Dworkin, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neuropathic pain, critically-ill patients (unlabeled use):",
"     </b>",
"     Oral: Initial: 100 mg 3 times daily in combination with I.V. opioids; maintenance: 300-1200 mg 3 times daily; maximum dose: 3600 mg daily (Barr, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Postherpetic neuralgia:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: Day 1: 300 mg, Day 2: 300 mg twice daily, Day 3: 300 mg 3 times/day; dose may be titrated as needed for pain relief (range: 1800-3600 mg/day in divided doses, daily doses &gt;1800 mg do not generally show greater benefit)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release (Gralise&trade;): Day 1: 300 mg, Day 2: 600 mg, Days 3-6: 900 mg once daily, Days 7-10: 1200 mg once daily, Days 11-14: 1500 mg once daily, Days &ge;15: 1800 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Postoperative pain (adjunct; unlabeled use):",
"     </b>",
"     Oral: Immediate release: Usual dose: 300-1200 mg given the night before or 1-2 hours prior to surgery (Dauri, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Restless legs syndrome (RLS) (unlabeled use):",
"     </b>",
"     Oral: Initial: 300 mg once daily 2 hours before bedtime. Doses &ge;600 mg/day have been given in 2 divided doses (late afternoon and 2 hours before bedtime). Dose may be titrated every 2 weeks until symptom relief achieved  (range: 300-1800 mg/day). Suggested maintenance dosing schedule: One-third of total daily dose given at 12 pm, remaining two-thirds total daily dose given at 8 pm. (Garcia-Borreguero, 2002; Happe, 2003; Saletu, 2010; Vignatelli, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Vasomotor symptoms associated with menopause  (unlabeled use):",
"     </b>",
"     Oral: Day 1: 300 mg at bedtime, Day 2: 300 mg twice daily, followed by 300 mg 3 times/day for 4 weeks and then tapered off  (Butt, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F175044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/23/35191?source=see_link\">",
"      see \"Gabapentin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anticonvulsant:",
"     </b>",
"     Oral: Immediate release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children 3-12 years:",
"     </i>",
"     Initial: 10-15 mg/kg/day in 3 divided doses; titrate to effective dose over ~3 days; dosages of up to 50 mg/kg/day have been tolerated in clinical studies",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Children 3-4 years:",
"     </i>",
"     Usual dose: 40 mg/kg/day in 3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Children 5-12 years:",
"     </i>",
"     Usual dose: 25-35 mg/kg/day in 3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Children &gt;12 years:",
"     </i>",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     If gabapentin is discontinued or if another anticonvulsant is added to therapy, it should be done slowly over a minimum of 1 week",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F175028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Studies in elderly patients have shown a decrease in clearance as age increases. This is most likely due to age-related decreases in renal function; dose reductions may be needed.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F175029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;12 years and Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Immediate release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: 300-1200 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30-59 mL/minute: 200-700 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;15-29 mL/minute: 200-700 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15 mL/minute: 100-300 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute: Reduce daily dose in proportion to creatinine clearance based on dose for creatinine clearance of 15 mL/minute (eg, reduce dose by one-half [range: 50-150 mg/day] for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     7.5 mL/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ESRD requiring hemodialysis: Dose for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;15 mL/minute plus single supplemental dose of 125-350 mg (given after each 4 hours of hemodialysis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Extended release:",
"     <b>",
"      Note:",
"     </b>",
"     Follow initial dose titration schedule if treatment-naive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;60 mL/minute: 1800 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;30-59 mL/minute: 600-1800 mg once daily; dependent on tolerability and clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ESRD requiring hemodialysis: Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13297683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, gabapentin is not hepatically metabolized.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F174997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 100 mg, 300 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neurontin&reg;: 100 mg, 300 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 250 mg/5 mL (470 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neurontin&reg;: 250 mg/5 mL (470 mL) [cool strawberry-anise flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 600 mg, 800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gralise&trade;: 300 mg [contains soybean lecithin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gralise&trade;: 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neurontin&reg;: 600 mg, 800 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [combination package (each unit-dose starter kit contains)]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gralise&trade;: 300 mg (9s) [white tablets; contains soybean lecithin] and 600 mg (69s) [beige tablets]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F174981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10916634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neurontin&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM229208.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM229208.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gralise&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM245196.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM245196.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F175001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, solution (immediate release): Administer first dose on first day at bedtime to avoid somnolence and dizziness. Dosage must be adjusted for renal function; when given 3 times daily, the maximum time between doses should not exceed 12 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet (extended release): Take with evening meal. Swallow whole; do not chew, crush, or split.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F175000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct for treatment of partial seizures with and without secondary generalized seizures in patients &gt;12 years of age with epilepsy; adjunct for treatment of partial seizures in pediatric patients 3-12 years of age; management of postherpetic neuralgia (PHN) in adults",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F175056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Neuropathic pain, diabetic peripheral neuropathy, fibromyalgia, postoperative pain (adjunct), restless legs syndrome (RLS), vasomotor symptoms",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F175068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Neurontin&reg; may be confused with Motrin&reg;, Neoral&reg;, nitrofurantoin, Noroxin&reg;, Zarontin&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F175058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As reported for immediate release (IR) formulations in patients &gt;12 years of age, unless otherwise noted in children (3-12 years) or with use of extended release (ER) formulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (IR: 17% to 28%; children 3%; ER: 11%), somnolence (IR: 19% to 21%; children 8%; ER: 5%), ataxia (3% to 13%), fatigue (11%; children 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (children 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (IR: 2% to 8%; ER: 4%), vasodilatation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (children 10%), hostility (children 5% to 8%), emotional lability (children 4% to 6%), headache (IR: 3%; ER: 4%), abnormal thinking (2% to 3%; children 2%), amnesia (2%), depression (2%), nervousness (2%), abnormal coordination (1% to 2%), pain (ER: 1% to 2%), hyperesthesia (1%), lethargy (ER: 1%), twitching (1%), vertigo (ER: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (1%), rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (IR: 6%; ER: 3%), nausea/vomiting (3% to 4%; children 8%), abdominal pain (3%), xerostomia (IR: 2% to 5%; ER: 3%), constipation (IR: 1% to 4%; ER: 1%), weight gain (IR: adults and children 2% to 3%; ER: 2%), dyspepsia (IR: 2%; ER: 1%), flatulence (2%), dry throat (2%), dental abnormalities (2%), appetite stimulation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence (2%), urinary tract infection (ER: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Decreased WBC (1%), leukopenia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (7%), weakness (6%), hyperkinesia (children 3% to 5%), abnormal gait (2%), back pain (IR: 2%; ER: 2%), dysarthria (2%), limb pain (ER: 2%), myalgia (2%), fracture (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Nystagmus (8%), diplopia (1% to 6%), blurred vision (3% to 4%), conjunctivitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Otitis media (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (4%), bronchitis (children 3%), nasopharyngitis (ER: 3%), respiratory infection (children 3%), pharyngitis (1% to 3%), cough (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and case reports (Limited to important or life-threatening): Acute renal failure, anemia, angina, angioedema, aphasia, arrhythmias (various), aspiration pneumonia, blindness, bradycardia, breast enlargement, cerebrovascular accident, CNS tumors, coagulation defect, colitis, CPK increased, Cushingoid appearance, encephalopathy, erythema multiforme, facial paralysis, fecal incontinence, gastroenteritis, glaucoma, glycosuria, hearing loss, heart block, heart failure, hematemesis, hematuria, hemiplegia, hemorrhage, hepatitis, hepatomegaly, herpes zoster, hyperlipidemia, hyper-/hypotension, hyper-/hypothyroidism, hyponatremia, jaundice, leukocytosis, liver function tests increased, local myoclonus, lymphadenopathy, lymphocytosis, meningismus, MI, migraine, nephrosis, nerve palsy, non-Hodgkin's lymphoma, ovarian failure, pancreatitis, peptic ulcer, pericardial effusion, pericardial rub, pericarditis, peripheral vascular disorder, pneumonia, psychosis, pulmonary embolus, pulmonary thrombosis, renal stone, retinopathy, skin necrosis, status epilepticus, Stevens-Johnson syndrome, subdural hematoma, suicidal behavior/ideation, syncope, tachycardia, thrombocytopenia, thrombophlebitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F175005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to gabapentin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F174985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multiorgan hypersensitivity: Potentially serious, sometimes fatal multiorgan hypersensitivity (also known as drug reaction with eosinophilia and systemic symptoms [DRESS]) has been reported with some antiepileptic drugs, including gabapentin. Monitor for signs and symptoms of possible disparate manifestations associated with lymphatic, hepatic, renal, cardiac, and/or hematologic systems; fever, rash, and eosinophilia may also be present. Discontinue immediately if suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal ideation: Pooled analysis of trials involving various antiepileptics (regardless of indication) showed an increased risk of suicidal thoughts/behavior (incidence rate: 0.43% treated patients compared to 0.24% of patients receiving placebo); risk observed as early as 1 week after initiation and continued through duration of trials (most trials &le;24 weeks). Monitor all patients for notable changes in behavior that might indicate suicidal thoughts or depression; notify healthcare provider immediately if symptoms occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment; dose adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: The safety and efficacy of extended release gabapentin (Gralise&trade;) has not been studied in patients with epilepsy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product interchangeability: Gabapentin immediate release and extended release (Gralise&trade;) products are not interchangeable with each other",
"     <b>",
"      or",
"     </b>",
"     with gabapentin enacarbil (Horizant&trade;) due to differences in formulations, indications, and pharmacokinetics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumorigenic potential: Male rat studies demonstrated an association with pancreatic adenocarcinoma (clinical implication in humans is unknown).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal. Gralise&trade; should be withdrawn over &ge;1 week.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F174990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Gabapentin. Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F175018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Tablet, solution (immediate release): No significant effect on rate or extent of absorption; tablet (extended release): Increases rate and extent of absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid evening primrose (seizure threshold decreased). Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F174993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F175008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Gabapentin crosses the placenta. In a small study (n=6), the umbilical/maternal plasma concentration ratio was ~1.74. Neonatal concentrations declined quickly after delivery and at 24 hours of life were ~27% of the cord blood concentrations at birth (gabapentin neonatal half-life ~14 hours) (Ohman, 2005). Outcome data following maternal use of gabapentin during pregnancy is limited (Holmes, 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients exposed to gabapentin during pregnancy are encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334. Additional information is available at www.aedpregnancyregistry.org.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F175033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F175009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gabapentin is excreted in human breast milk. Per the manufacturer, a nursed infant could be exposed to ~1 mg/kg/day of gabapentin; the effect on the child is not known. Use in breast-feeding women only if the benefits to the mother outweigh the potential risk to the infant.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In a small study of breast-feeding women (n=6), the estimated exposure of gabapentin to the nursing infants was ~1% to 4% of the weight-adjusted maternal dose (sampling occurred from 12-97 days after delivery and maternal doses ranged from 600-2100 mg daily). Gabapentin was detected in the serum of 2 nursing infants 2-3 weeks after delivery and in 1 infant after 3 months of breast-feeding. Serum concentrations were &lt;12% of the maternal plasma concentrations and &lt;5% of those measured in the umbilical cord. Adverse events were not reported in the breast-fed infants (Ohman, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F175010\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Immediate release tablet and solution may be taken without regard to meals; extended release tablet should be taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F175007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Gabapentin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $53.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $133.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $159.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Neurontin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $111.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (50): $151.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (50): $176.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Gabapentin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg/5 mL (470 mL): $148.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Neurontin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg/5 mL (470 mL): $207.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Gabapentin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (100): $252.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800 mg (100): $303.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Gralise Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (30): $90.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (90): $272.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Neurontin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (100): $527.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800 mg (100): $633.25",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F174995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor serum levels of concomitant anticonvulsant therapy; suicidality (eg, suicidal thoughts, depression, behavioral changes)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F175011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alpentin (ID);",
"     </li>",
"     <li>",
"      Bapex (MX);",
"     </li>",
"     <li>",
"      Barontin (KP);",
"     </li>",
"     <li>",
"      Blugat (MX);",
"     </li>",
"     <li>",
"      Calmpent (PH);",
"     </li>",
"     <li>",
"      Carbatin (TW);",
"     </li>",
"     <li>",
"      Die Li (CL);",
"     </li>",
"     <li>",
"      Dineurin (CN);",
"     </li>",
"     <li>",
"      Engaba (PK);",
"     </li>",
"     <li>",
"      Epiven (ID);",
"     </li>",
"     <li>",
"      Epleptin (ZA);",
"     </li>",
"     <li>",
"      Gabadin (PY);",
"     </li>",
"     <li>",
"      Gabahexal (AU);",
"     </li>",
"     <li>",
"      Gabantin (MX);",
"     </li>",
"     <li>",
"      Gabapenin (KP);",
"     </li>",
"     <li>",
"      Gabaran (AU);",
"     </li>",
"     <li>",
"      Gabaron (PH);",
"     </li>",
"     <li>",
"      Gabatin (CH, KP);",
"     </li>",
"     <li>",
"      Gabatine (AU);",
"     </li>",
"     <li>",
"      Gabenil (HK);",
"     </li>",
"     <li>",
"      Gabexol (ID);",
"     </li>",
"     <li>",
"      Gabix (PH);",
"     </li>",
"     <li>",
"      Gabutin (TH);",
"     </li>",
"     <li>",
"      Ganin (ID);",
"     </li>",
"     <li>",
"      Gantin (AU);",
"     </li>",
"     <li>",
"      Gapatin (TW);",
"     </li>",
"     <li>",
"      Gapridol (MX);",
"     </li>",
"     <li>",
"      Gaty (TW);",
"     </li>",
"     <li>",
"      Gonnaz (PH);",
"     </li>",
"     <li>",
"      Nepatic (ID);",
"     </li>",
"     <li>",
"      Neuleptol (KP);",
"     </li>",
"     <li>",
"      Neuril (DK);",
"     </li>",
"     <li>",
"      Neurontin (AE, AR, AT, AU, BE, BG, BH, BO, BR, CH, CL, CO, CR, CY, CZ, DE, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, HU, ID, IE, IL, IN, IQ, IR, IT, JO, KE, KP, KW, LB, LY, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PL, PR, PT, QA, RU, SA, SE, SG, SV, SY, TH, TR, TW, UY, VE, YE, ZA);",
"     </li>",
"     <li>",
"      Neverpentin (TH);",
"     </li>",
"     <li>",
"      New-GABA (KP);",
"     </li>",
"     <li>",
"      Nopatic (MX);",
"     </li>",
"     <li>",
"      Nupentin (AU, NZ, SG);",
"     </li>",
"     <li>",
"      Pendine (AU);",
"     </li>",
"     <li>",
"      Pengatine (KP);",
"     </li>",
"     <li>",
"      Reinin (PH);",
"     </li>",
"     <li>",
"      Remaltin (TW);",
"     </li>",
"     <li>",
"      Rontin (TH);",
"     </li>",
"     <li>",
"      Sipentin (ID);",
"     </li>",
"     <li>",
"      Vultin (HK, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F174984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gabapentin is structurally related to GABA. However, it does not bind to GABA",
"     <sub>",
"      A",
"     </sub>",
"     or GABA",
"     <sub>",
"      B",
"     </sub>",
"     receptors, and it does not appear to influence synthesis or uptake of GABA. High affinity gabapentin binding sites have been located throughout the brain; these sites correspond to the presence of voltage-gated calcium channels specifically possessing the alpha-2-delta-1 subunit. This channel appears to be located presynaptically, and may modulate the release of excitatory neurotransmitters which participate in epileptogenesis and nociception.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F175004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Variable, from proximal small bowel by L-amino transport system",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 58 &plusmn; 6 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;3%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Inversely proportional to dose due to saturable absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     900 mg/day: 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1200 mg/day: 47%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2400 mg/day: 34%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     3600 mg/day: 33%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4800 mg/day: 27%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: Variable; increased with higher fat content meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 5-7 hours; anuria 132 hours; during dialysis 3.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Immediate release: 2-4 hours; extended release: 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Proportional to renal function; urine (as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Adler CH, &ldquo;Treatment of Restless Legs Syndrome With Gabapentin,&rdquo;",
"      <i>",
"       Clin Neuropharmacol",
"      </i>",
"      , 1997, 20(2):148-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/9099467/pubmed\" id=\"9099467\" target=\"_blank\">",
"        9099467",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Andrews CO and Fischer JH, &ldquo;Gabapentin: A New Agent for the Management of Epilepsy,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1994, 28(10):1188-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/7841578/pubmed\" id=\"7841578\" target=\"_blank\">",
"        7841578",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Attal N, Cruccu G, Baron R, et al, \"EFNS Guidelines on the Pharmacological Treatment of Neuropathic Pain: 2010 Revision,\"",
"      <i>",
"       Eur J Neurol",
"      </i>",
"      , 2010, 17(9):1113-e88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/20402746/pubmed\" id=\"20402746\" target=\"_blank\">",
"        20402746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barr J, Fraser G, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(1):263-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/23269131/pubmed\" id=\"23269131\" target=\"_blank\">",
"        23269131",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bourgeois BF, &ldquo;Antiepileptic Drugs in Pediatric Practice,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1995, 36(Suppl 2):34-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/8784213/pubmed\" id=\"8784213\" target=\"_blank\">",
"        8784213",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bril V, England J, Franklin GM, et al, \"Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2011, 76(20):1758-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/21482920/pubmed\" id=\"21482920\" target=\"_blank\">",
"        21482920",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brown JT and Randall A, &ldquo;Gabapentin Fails to Alter P/Q-Type Ca2+ Channel-Mediated Synaptic Transmission in the Hippocampus",
"      <i>",
"       in vitro",
"      </i>",
"      ,&rdquo;",
"      <i>",
"       Synapse",
"      </i>",
"      , 2005, 55(4):262-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/15668986/pubmed\" id=\"15668986\" target=\"_blank\">",
"        15668986",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Butt DA, Lock M, Lewis JE, et al, &ldquo;Gabapentin for the Treatment of Menopausal Hot Flashes: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Menopause",
"      </i>",
"      , 2008, 15(2):310-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/17917611/pubmed\" id=\"17917611\" target=\"_blank\">",
"        17917611",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dauri M, Faria S, Gatti A, et al, \"Gabapentin and Pregabalin for the Acute Post-operative Pain Management. A Systematic-Narrative Review of the Recent Clinical Evidences,\"",
"      <i>",
"       Curr Drug Targets",
"      </i>",
"      , 2009, 10(8):716-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/19702520/pubmed\" id=\"19702520\" target=\"_blank\">",
"        19702520",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dworkin RH, O'Connor AB, Audette J, et al, \"Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature Update,\"",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 2010, 85(3 Suppl):3-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/20194146/pubmed\" id=\"20194146\" target=\"_blank\">",
"        20194146",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fischer JH, Barr AN, Rogers SL, et al, &ldquo;Lack of Serious Toxicity Following Gabapentin Overdose,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1994, 44(5):982-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/8190316/pubmed\" id=\"8190316\" target=\"_blank\">",
"        8190316",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garcia-Borreguero D, Larrosa O, de la Llave Y, et al, &rdquo;Treatment of Restless Legs Syndrome With Gabapentin: A Double-Blind, Cross-Over Study,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2002, 59(10):1573-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/12451200/pubmed\" id=\"12451200\" target=\"_blank\">",
"        12451200",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goa KL and Sorkin EM, &ldquo;Gabapentin: A Review of Its Pharmacological Properties and Clinical Potential in Epilepsy,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1993, 46(3):409-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/7693432/pubmed\" id=\"7693432\" target=\"_blank\">",
"        7693432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Happe S, Sauter C, Klosch G, et al, &ldquo;Gabapentin Versus Ropinirole in the Treatment of Idiopathic Restless Legs Syndrome,&rdquo;",
"      <i>",
"       Neuropsychobiology",
"      </i>",
"      , 2003, 48(2):82-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/14504416/pubmed\" id=\"14504416\" target=\"_blank\">",
"        14504416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holmes LB and Hernandez-Diaz S, \"Newer Anticonvulsants: Lamotrigine, Topiramate, and Gabapentin,\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2012, 94(8):599-606.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/22730257/pubmed\" id=\"22730257\" target=\"_blank\">",
"        22730257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khurana DS, Riviello J, Helmers S, et al, &ldquo;Efficacy of Gabapentin Therapy in Children With Refractory Partial Seizures,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1996, 128(6):829-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/8648543/pubmed\" id=\"8648543\" target=\"_blank\">",
"        8648543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee DO, Steingard RJ, Cesena M, et al, &ldquo;Behavioral Side Effects of Gabapentin in Children,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1996, 37(1):87-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/8603631/pubmed\" id=\"8603631\" target=\"_blank\">",
"        8603631",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leiderman D, Garofalo E, and LaMoreaux L, &ldquo;Gabapentin Patients With Absence Seizures: Two Double-Blind, Placebo Controlled Studies,&rdquo;",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 1993, 34(Suppl 6):45.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mellick LB and Mellick GA, &ldquo;Successful Treatment of Reflex Sympathetic Dystrophy With Gabapentin,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1995, 13(1):96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/7832967/pubmed\" id=\"7832967\" target=\"_blank\">",
"        7832967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ohman I, Vitols S, and Tomson T, \"Pharmacokinetics of Gabapentin During Delivery, in the Neonatal Period, and Lactation:Does a Fetal Accumulation Occur During Pregnancy?\"",
"      <i>",
"       Epilepsia",
"      </i>",
"      , 2005, 46(10):1621-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/16190933/pubmed\" id=\"16190933\" target=\"_blank\">",
"        16190933",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saletu M, Anderer P, Saletu-Zyhlarz GM, et al, &ldquo;Comparative Placebo-Controlled Polysomnographic and Psychometric Studies on the Acute Effects of Gabapentin Versus Ropinirole in Restless Legs Syndrome,&rdquo;",
"      <i>",
"       J Neural Transm",
"      </i>",
"      , 2010, 117(4):463-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/20049491/pubmed\" id=\"20049491\" target=\"_blank\">",
"        20049491",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Short C and Cooke L, &ldquo;Hypomania Induced by Gabapentin,&rdquo;",
"      <i>",
"       Br J Psychiatry",
"      </i>",
"      , 1995, 166(5):679-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/7620760/pubmed\" id=\"7620760\" target=\"_blank\">",
"        7620760",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sills GJ, &ldquo;The Mechanisms of Action of Gabapentin and Pregabalin,&rdquo;",
"      <i>",
"       Curr Opin Pharmacol",
"      </i>",
"      , 2006, 6(1):108-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/16376147/pubmed\" id=\"16376147\" target=\"_blank\">",
"        16376147",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vignatelli L, Billiard M, Clarenbach P, et al,  &ldquo;EFNS Guidelines on Management of Restless Leg Syndrome and Periodic Limb Movement Disorder in Sleep,&rdquo;",
"      <i>",
"       Eur J Neurol",
"      </i>",
"      , 2006, 13(10):1049-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/19/19768/abstract-text/16987157/pubmed\" id=\"16987157\" target=\"_blank\">",
"        16987157",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8483 Version 52.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C801F8800B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_19_19768=[""].join("\n");
var outline_f19_19_19768=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175023\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175024\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175060\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175027\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175044\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175028\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175029\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13297683\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174997\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174981\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10916634\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175001\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175000\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175056\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175068\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175058\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175005\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174985\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299373\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174990\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175018\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174993\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175008\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175033\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175009\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175010\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175007\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174995\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175011\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174984\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175004\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8483\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8483|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/8/2182?source=related_link\">",
"      Gabapentin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/23/35191?source=related_link\">",
"      Gabapentin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_19_19769="Clinical manifestations, diagnosis, and treatment of Campylobacter infection";
var content_f19_19_19769=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and treatment of Campylobacter infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/19/19769/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/19/19769/contributors\">",
"     Ban M Allos, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/19/19769/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/19/19769/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/19/19769/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/19/19769/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/19/19769/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Campylobacter infection is an important cause of acute diarrhea worldwide; Campylobacter enteritis is typically caused by Campylobacter jejuni or Campylobacter coli. The organism inhabits the intestinal tracts of a wide range of animal hosts, notably poultry; contamination from these sources can lead to foodborne disease. Campylobacter infection can also be transmitted via water-borne outbreaks and direct contact with animals or animal products.",
"   </p>",
"   <p>",
"    Issues related to clinical manifestations, diagnosis and treatment of Campylobacter infection will be reviewed here. Issues related to microbiology, pathogenesis, and epidemiology of Campylobacter infection are discussed separately, as are issues related to less-common Campylobacter species. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5065?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of Campylobacter infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19368?source=see_link\">",
"     \"Infection with less common Campylobacter species and related bacteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of Campylobacter enteritis due to C. jejuni and C. coli are clinically indistinguishable from one another and from illness due to other bacterial pathogens, such as Salmonellae or Shigellae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2642806\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean incubation period is three days (range one to seven days) (",
"    <a class=\"graphic graphic_figure graphicRef55054 \" href=\"UTD.htm?37/36/38478\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Early symptoms include abrupt onset of abdominal pain and diarrhea. In about one-third of cases, a prodromal period characterized by high fever accompanied by rigors, generalized aches, dizziness, and delirium is observed. It may last for one day (rarely two or three days) prior to onset of gastrointestinal symptoms. Patients presenting with prodromal symptoms tend to have more severe disease than those presenting with diarrhea.",
"   </p>",
"   <p>",
"    The acute illness is characterized by cramping, periumbilical abdominal pain, and diarrhea. Patients frequently report ten or more bowel movements per day [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/4\">",
"     4",
"    </a>",
"    ]. Bloody stools are observed on the second or third day of diarrhea in about 15 percent of patients; infection with an organism containing plasmid pVir may be correlated with more severe invasive disease and higher likelihood of bloody diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Abdominal pain also may occur without diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/7\">",
"     7",
"    </a>",
"    ]. The pain may become continuous and radiate to the right iliac fossa, mimicking acute appendicitis. Nausea is common; approximately 15 to 25 percent of patients report vomiting.",
"   </p>",
"   <p>",
"    Transient bacteremia may be present in the early stages of infection. In the US and Europe, bacteremia has been reported to occur in 0.1 to 1 percent of campylobacter cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. Bacteremia appears to occur more frequently among immunosuppressed patients or those with other comorbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/9,12\">",
"     9,12",
"    </a>",
"    ], although a surveillance study in Finland noted that 53 of 76 cases of bacteremia (70 percent) occurred in patients without any underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/10\">",
"     10",
"    </a>",
"    ]. A mild neutrophilic leukocytosis with bandemia is common [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diarrhea is self-limited and lasts for a mean of seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Abdominal pain may persist after resolution of diarrhea, and weight loss of 5 kg or more may be observed. Organisms may be excreted in the feces for several weeks after clinical recovery. One study reported a mean excretion period of 38 days [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/1\">",
"     1",
"    </a>",
"    ]. Chronic carriage can occur in patients with immune deficiency, although follow-up cultures are not necessary in the absence of clinical symptoms Relapse may occur in 5 to 10 percent of patients.",
"   </p>",
"   <p>",
"    The case fatality rate is low and most deaths occur in the elderly or others with comorbid conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/8,12,16\">",
"     8,12,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations in children include diarrhea, fever, abdominal pain, and vomiting. Bloody stools may be present in more than half of children. Fever tends to be pronounced in children over one year of age and convulsions may occur. In a large milk-borne outbreak of Campylobacter enteritis affecting 2500 children, 9 were hospitalized with grand mal seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/17\">",
"     17",
"    </a>",
"    ]. The seizures arose prior to onset of diarrhea and their illnesses were unusually severe. Meningismus and encephalopathy have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In infants, vomiting and bloody stools are frequently observed; abdominal pain and fever are less common than in older children [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/19\">",
"     19",
"    </a>",
"    ]. The presentation of bloody stools in the absence of diarrhea or fever can mimic intussusception. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=see_link\">",
"     \"Intussusception in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among neonates with C. jejuni infection, grossly bloody stools or fever may be the only manifestations of infection. Neonatal infection is usually acquired at the time of birth from a mother who is excreting Campylobacter organism in her stools (with or without a history of recent diarrhea). Nosocomial infection in neonatal nurseries has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2643607\">",
"    <span class=\"h2\">",
"     HIV coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increased incidence of Campylobacter infection in patients with",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Long-term carriage can occur, which can be associated with recurrent episodes of enteritis and bacteremia. Campylobacter infection in patients with HIV infection has been associated with severe, debilitating illness [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Unique manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Campylobacter infection can present with clinical manifestations mimicking other diseases (eg, \"pseudoappendicitis\" and colitis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pseudoappendicitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe abdominal pain prior to onset of diarrhea can mimic acute appendicitis. In some cases, diarrhea is absent (this is most frequently observed among children aged 6 to 15 years). The pain is caused by acute ileocecitis. On clinical examination, tenderness may be observed; rebound tenderness and guarding are usually absent.",
"   </p>",
"   <p>",
"    Ultrasound or computed tomography examination may be useful for differentiating bacterial ileocecitis from acute appendicitis. In one series of 533 patients with suspected acute appendicitis or appendiceal mass, 61 had ultrasonographic findings indicating enlarged mesenteric lymph nodes and mural thickening of the terminal ileum and cecum, but there was no image of the appendix [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/23\">",
"     23",
"    </a>",
"    ]. Of these 61 patients, 41 had confirmed infection (21 with Yersinia enterocolitica and 15 with C. jejuni).",
"   </p>",
"   <p>",
"    Among patients with Campylobacter infection who undergo appendectomy, in most cases the removed appendix shows little or no inflammation, although evidence of Campylobacter infection has been found in up to 3 percent of inflamed appendices removed surgically [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/24\">",
"     24",
"    </a>",
"    ]. Thus, Campylobacter-induced appendicitis is probably a real, though uncommon, entity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Campylobacter infection usually starts in the jejunum and ileum and progresses distally to affect the cecum and colon. However, some patients present with acute colitis and bloody diarrhea, which can mimic the acute colitis of inflammatory bowel disease (IBD) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/25\">",
"     25",
"    </a>",
"    ]. Histologic examination of the rectal or colonic mucosa in patients with Campylobacter colitis demonstrates acute inflammation without the chronic changes and crypt distortion usually seen in IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that Campylobacter infection may play a role in the pathogenesis of IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsy specimens from patients with immunoproliferative small intestinal disease have demonstrated evidence of C. jejuni, suggesting the possibility of an association between C. jejuni infection and lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/29\">",
"     29",
"    </a>",
"    ]. Additional investigation may lead to new insights into the pathogenesis of C. jejuni infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2642663\">",
"    <span class=\"h3\">",
"     Acute onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute complications of Campylobacter enteritis include [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cholecystitis, with or without preceding diarrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Peritonitis in patients on continuous ambulatory peritoneal dialysis, usually with preceding diarrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Rash (such as urticaria, erythema nodosum, vasculitis, cellulitis) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Septic pseudoaneurysm [",
"      <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pericarditis and myocarditis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. The typical clinical presentation involves acute chest pain, with electrocardiogram changes, and elevated levels of cardiac enzymes, in association with antecedent or coincident enteritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Focal extraintestinal infections with C. jejuni and C. coli occur uncommonly, with or without preceding diarrhea. Examples include septic arthritis, bursitis, osteitis, soft tissue infections, and",
"    <span class=\"nowrap\">",
"     fetal/placental",
"    </span>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/4\">",
"     4",
"    </a>",
"    ]. Campylobacter abortion is also caused by C. fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19368?source=see_link\">",
"     \"Infection with less common Campylobacter species and related bacteria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Late onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major late onset complications of Campylobacter infection: reactive arthritis and Guillain-Barr&eacute; syndrome (GBS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h4\">",
"     Reactive arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reactive arthritis associated with Campylobacter enteritis is similar to arthritis that can occur following Salmonella, Shigella, and other bacterial diarrheal infections. The rate of reactive arthritis is fairly low (up to 2.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/4,37-39\">",
"     4,37-39",
"    </a>",
"    ], although the prevalence of joint symptoms may be as high as 9 to 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The likelihood of developing reactive arthritis following C. jejuni infection appears to be unrelated to the severity of diarrheal illness [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/42\">",
"     42",
"    </a>",
"    ]. Reactive arthritis occurs more commonly among patients with the HLA-B27 phenotype.",
"   </p>",
"   <p>",
"    Joint pain and swelling typically appear one to two weeks (or occasionally several weeks) after the onset of diarrhea. The ankles, knees, wrists, and small joints of the hands are most frequently affected, often with considerable incapacity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/43\">",
"     43",
"    </a>",
"    ]. The duration of arthritis ranges from one week to several months. The prognosis is usually good; most patients remit spontaneously or with NSAID therapy within six months of onset. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h4\">",
"     Guillain-Barr&eacute; syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. jejuni infection has been established as a trigger of GBS, an acute immune-mediated polyneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. It has been estimated that 30 to 40 percent of GBS illness is attributable to Campylobacter infection, which typically occurs between one and two weeks before the onset of neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/45\">",
"     45",
"    </a>",
"    ]. Campylobacter-associated GBS is more likely to be associated with the axonal form of GBS (as opposed to the demyelinating form). GBS occurring after infection with C. jejuni has a worse prognosis than other forms of GBS; recovery is slower and the likelihood of residual neurologic disability is greater than with other forms of GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=see_link\">",
"     \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=see_link\">",
"     \"Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk for developing GBS during the two months following a symptomatic episode of C. jejuni infection is approximately 100-fold higher than the risk of developing GBS in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. In the United States, about 1 in 1000 patients with Campylobacter enteritis develops GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/45\">",
"     45",
"    </a>",
"    ]. Subclinical cases of Campylobacter infection can also trigger GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GBS associated with C. jejuni infection is likely caused by antibodies formed in response to epitopes expressed by the infecting Campylobacter strain that are cross-reactive to GM1 ganglioside (present in high concentrations in peripheral nerve myelin) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Many Campylobacter strains isolated from patients with GBS belong to specific serotypes, notably Penner O19 and 041 strains [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/53-55\">",
"     53-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The production of antibodies to GM1 ganglioside may also occur due to mechanisms other than molecular mimicry [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/44\">",
"     44",
"    </a>",
"    ], and many patients with Campylobacter infection form these antibodies in the absence of neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/50\">",
"     50",
"    </a>",
"    ]. Some studies have suggested there may be an association between certain HLA types and the likelihood of developing GBS following C. jejuni infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/33,56,57\">",
"     33,56,57",
"    </a>",
"    ]. Others have been unable to confirm this association [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Miller-Fisher variant of GBS, in which the cranial nerves are more prominently affected, has also been associated with Campylobacter infection. Cross-reacting antibodies to GQ1b ganglioside (which is present in cranial nerve myelin) have been observed in these cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/44\">",
"     44",
"    </a>",
"    ]. The most common serotype observed in C. jejuni-associated Miller-Fisher syndrome is Penner O2 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Campylobacter enteritis should be suspected in the setting of severe abdominal pain with diarrhea. Clinical history including details related to meals eaten at communal functions and contact with others who have similar symptoms are important for public health purposes.",
"   </p>",
"   <p>",
"    The diagnosis is established by stool culture. Culture technique consists of plating on Campylobacter selective media and incubation in a gas mixture of 5 to 10 percent oxygen, 1 to 10 percent carbon dioxide, and ideally some hydrogen (",
"    <a class=\"graphic graphic_picture graphicRef69842 \" href=\"UTD.htm?34/43/35518\">",
"     picture 1",
"    </a>",
"    ). Campylobacter have a characteristic appearance under the microscope, which, together with detection of oxidase and catalase positivity, is sufficient for diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5065?source=see_link&amp;anchor=H4#H4\">",
"     \"Microbiology, pathogenesis, and epidemiology of Campylobacter infection\", section on 'Detection in the laboratory'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is customary for laboratories to report the presence of \"Campylobacter\" or \"Campylobacter jejuni\" without differentiating C. jejuni from C. coli. This is acceptable for routine diagnostic purposes since the distinction is of no clinical consequence, but speciation and strain identification is sometimes needed for epidemiological purposes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5065?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of Campylobacter infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In rare cases of acute colitis or suspected appendicitis in which a rapid diagnosis is needed for clinical management, presumptive identification is possible by stool microscopic examination using dark-field, phase-contrast, and stained smears. This technique is less sensitive than culture (50 to 94 percent) and is not practiced routinely. Gram stain is even less sensitive. C. jejuni appear as faint, gram-negative curved rods (",
"    <a class=\"graphic graphic_picture graphicRef78674 \" href=\"UTD.htm?14/34/14895\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5065?source=see_link&amp;anchor=H4#H4\">",
"     \"Microbiology, pathogenesis, and epidemiology of Campylobacter infection\", section on 'Detection in the laboratory'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with late onset reactive arthritis or Guillain-Barr&eacute; syndrome (GBS) may have negative stool studies. Serologic tests can be used to detect recent Campylobacter infection in these patients. In one study, a complement fixation test (using whole-cell antigens) had greatest sensitivity compared with ELISA and other tests [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/60\">",
"     60",
"    </a>",
"    ]. In general, these tests are available only in reference laboratories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Campylobacter infection is usually a mild, self-limited infection. The estimated mortality from symptomatic infection in the United States is 2.4 per 1000 culture-confirmed cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Maintenance of proper hydration and correction of electrolyte abnormalities should be the focus of therapy. Antibiotics are not needed for most cases of C. jejuni gastroenteritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Antimicrobial therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of antimicrobial therapy for Campylobacter infection has been addressed in a small number of randomized trials. A meta-analysis of 11 small randomized trials noted that antimicrobial therapy reduced the duration of intestinal symptoms by only 1.3 days (95% CI 0.6-2.0 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/63\">",
"     63",
"    </a>",
"    ]. There was a nonsignificant trend toward greater benefit for patients treated within the first three days of illness.",
"   </p>",
"   <p>",
"    Given the self-limited nature of most Campylobacter infections and the limited efficacy of routine antimicrobial therapy, treatment is warranted only for patients with severe disease or risk for severe disease. Patients with severe disease include individuals with bloody stools, high fever, extraintestinal infection, worsening or relapsing symptoms, or symptoms lasting longer than one week [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/61\">",
"     61",
"    </a>",
"    ]. Those at risk for severe disease include patients who are elderly, pregnant, or immunocompromised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Choice of drug",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. jejuni and C. coli are usually sensitive in vitro to macrolides, fluoroquinolones,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , tetracyclines, aminoglycosides, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    , although there are no data indicating clinical efficacy of clindamycin, tetracyclines, or chloramphenicol; the clinically relevant antibiotics to which Campylobacter are usually susceptible are the macrolides, fluoroquinolones, aminoglycosides, and carbapenems. However, resistance to fluoroquinolones and macrolides has been described. C. jejuni and C. coli are inherently resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    and beta-lactam antibiotics, including penicillin and most cephalosporins [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Resistance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    First line agents for treatment of Campylobacter gastroenteritis include fluoroquinolones (if sensitive) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/65-68\">",
"     65-68",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     Erythromycin",
"    </a>",
"    was previously favored although it is no longer favored as a first line agent, given toxicity and potential drug interactions. Azithromycin is particularly favored over erythromycin for patients on medications that inhibit CYP3A4 (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"     table 1",
"    </a>",
"    ) since concurrent use of erythromycin and such drugs can increase risk of sudden cardiac death [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/69\">",
"     69",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In patients with uncomplicated Campylobacter infection at risk for severe disease, we typically use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    500 mg po daily for three days or until signs and symptoms of disease have improved. For those with complications or underlying immunosuppression, a longer course (7 to 14 days) may be warranted. For patients who are severely ill and cannot tolerate oral therapy, treatment with an aminoglycoside or a carbapenem may be administered, but susceptibility testing should be performed. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of macrolide-resistance among Campylobacter has remained stable at &lt;5 percent in most parts of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/54,70-73\">",
"     54,70-73",
"    </a>",
"    ]. However, in some parts of the world, such as in Thailand and in Ireland, the macrolide-resistance rate is higher [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Despite an increase in macrolide resistance, macrolides are usually still effective in these areas. Drug susceptibility testing should be performed on isolates from patients failing therapy.",
"   </p>",
"   <p>",
"    The prevalence of fluoroquinolone resistant Campylobacter is rising. Resistance rates of greater than 50 percent have been reported in Spain, Hungary, and several developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/76\">",
"     76",
"    </a>",
"    ]. Foreign travel is a leading risk factor for the acquisition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    -resistant C. jejuni in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the rate of resistance to fluoroquinolones is also increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/14,70\">",
"     14,70",
"    </a>",
"    ]. The rate of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    resistance among Campylobacter isolated in the United States increased from 0 to 19 percent between 1989 and 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/70\">",
"     70",
"    </a>",
"    ]. Parallels in fluoroquinolone resistance have been observed between human isolates and strains isolated from poultry, reflecting the use of fluoroquinolones in food animals in the United States since 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/73,77-80\">",
"     73,77-80",
"    </a>",
"    ]. In one study, ciprofloxacin-resistant Campylobacter was isolated from 10 percent of 180 chicken products from grocery stores in three states [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/70\">",
"     70",
"    </a>",
"    ]. Molecular subtyping has confirmed the link between the human and poultry isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/14\">",
"     14",
"    </a>",
"    ]. Use of fluoroquinolones in poultry was withdrawn in the United States in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/81\">",
"     81",
"    </a>",
"    ]. Nonetheless, infections due to fluoroquinolone-resistant Campylobacter species are likely to persist due to continued circulation of such organisms in poultry flocks and from acquisition of quinolone resistant infection during foreign travel.",
"   </p>",
"   <p>",
"    In Southeast Asia, fluoroquinolone resistant Campylobacter is also an important problem. This is a particularly important consideration in the setting of returning travelers with significant diarrhea",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    who have failed empiric treatment with a fluoroquinolone) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interruption of transmission from poultry is a major factor in preventing human Campylobacter infection. Chicken should be cooked thoroughly. Utensils, cutting boards, and other items used in preparation of raw poultry should be washed thoroughly. Avoidance of unpasteurized dairy products is also an important preventive measure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adults with Campylobacter enteritis do not require special isolation; standard precautions are sufficient. Nosocomial infection in neonatal nurseries has been described. Infants and younger children in diapers with C. jejuni enteritis should be excluded from routine childcare centers until diarrhea has resolved (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Children'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Individuals with an acute diarrheal illness should not prepare or handle food until symptoms have resolved.",
"   </p>",
"   <p>",
"    There is no effective vaccine for prevention of Campylobacter infection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/19/19769/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/42/2723?source=see_link\">",
"       \"Patient information: Campylobacter infection (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2644129\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Campylobacter enteritis is an important cause of acute diarrhea worldwide. It is typically caused by Campylobacter jejuni or Campylobacter coli, and is largely a foodborne disease. The organism inhabits the intestinal tracts of a wide range of animal hosts, notably poultry; contamination from these sources can lead to foodborne disease. Campylobacter infection can also be transmitted via water-borne outbreaks and direct contact with animals or animal products. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mean incubation period is three days (range one to seven days) (",
"      <a class=\"graphic graphic_figure graphicRef55054 \" href=\"UTD.htm?37/36/38478\">",
"       figure 1",
"      </a>",
"      ). Early symptoms include abrupt onset of abdominal pain and diarrhea. The acute illness is characterized by cramping periumbilical abdominal pain and diarrhea. Patients frequently report ten or more bowel movements per day. Bloody stools are observed on the second or third day of diarrhea in about 15 percent of adults; in children bloody stools may be present in more than half of cases. Diarrhea is self-limited and lasts for a mean of seven days. (See",
"      <a class=\"local\" href=\"#H2642806\">",
"       'Adults'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with Campylobacter infection can present with clinical manifestations mimicking other diseases (eg, \"pseudoappendicitis\" and colitis). A variety of acute complications can occur. There are two major late onset complications of Campylobacter infection: reactive arthritis and Guillain-Barr&eacute; syndrome (GBS). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Unique manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of Campylobacter enteritis is established by stool culture. Patients with late onset reactive arthritis or GBS may have negative stool studies; serologic tests can be used to detect recent Campylobacter infection in these patients. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Campylobacter infection is usually a mild, self-limited infection. Maintenance of proper hydration and correction of electrolyte abnormalities should be the focus of therapy. Antibiotics are not needed for most cases of C. jejuni gastroenteritis. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe disease or risk for severe disease, we suggest treatment with a fluoroquinolone (if susceptible), or else a macrolide (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For uncomplicated infections in patients at risk for severe disease, we typically use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      500 mg po daily for three days or until signs and symptoms of disease have improved. For patients who cannot tolerate oral therapy, treatment with an aminoglycoside or a carbapenem may be administered. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Antimicrobial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Campylobacter resistance to macrolides and fluoroquinolones has been described. The rate of macrolide resistance among Campylobacter has remained stable at &lt;5 percent in most parts of the world; the prevalence of fluoroquinolone resistant Campylobacter is rising in many areas, particularly in Southeast Asia. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Resistance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/1\">",
"      Kapperud G, Lassen J, Ostroff SM, Aasen S. Clinical features of sporadic Campylobacter infections in Norway. Scand J Infect Dis 1992; 24:741.",
"     </a>",
"    </li>",
"    <li>",
"     Skirrow MB, Blaser MJ. Clinical aspects of Campylobacter infection. In: Campylobacter, 2nd ed, Nachamkin I, Blaser MJ (Eds), ASM Press, Washington DC 2000. p.69.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/3\">",
"      Blaser MJ, Berkowitz ID, LaForce FM, et al. Campylobacter enteritis: clinical and epidemiologic features. Ann Intern Med 1979; 91:179.",
"     </a>",
"    </li>",
"    <li>",
"     Skirrow MB, Blaser MJ. Campylobacter jejuni. In: Infections of the gastrointestinal tract, 2nd ed, Blaser MJ, Smith PD, Ravdin JI, et al (Eds), Lippincott Williams and Wilkins, Philadelphia 2002. p.719.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/5\">",
"      Tracz DM, Keelan M, Ahmed-Bentley J, et al. pVir and bloody diarrhea in Campylobacter jejuni enteritis. Emerg Infect Dis 2005; 11:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/6\">",
"      Louwen RP, van Belkum A, Wagenaar JA, et al. Lack of association between the presence of the pVir plasmid and bloody diarrhea in Campylobacter jejuni enteritis. J Clin Microbiol 2006; 44:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/7\">",
"      Matsuaki S, Katyama A. Studies of food poisoning due to outbreaks of Campylobacter jejuni between 1980 and 1982 in Yamaguchi prefecture, Japan. Yamaguchi J Vet Med 1984; 11:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/8\">",
"      Skirrow MB, Jones DM, Sutcliffe E, Benjamin J. Campylobacter bacteraemia in England and Wales, 1981-91. Epidemiol Infect 1993; 110:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/9\">",
"      Nielsen H, Hansen KK, Gradel KO, et al. Bacteraemia as a result of Campylobacter species: a population-based study of epidemiology and clinical risk factors. Clin Microbiol Infect 2010; 16:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/10\">",
"      Feodoroff B, Lauhio A, Ellstr&ouml;m P, Rautelin H. A Nationwide Study of Campylobacter jejuni and Campylobacter coli bacteremia in Finland over a 10-year period, 1998-2007, with special reference to clinical characteristics and antimicrobial susceptibility. Clin Infect Dis 2011; 53:e99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/11\">",
"      Samuel MC, Vugia DJ, Shallow S, et al. Epidemiology of sporadic Campylobacter infection in the United States and declining trend in incidence, FoodNet 1996-1999. Clin Infect Dis 2004; 38 Suppl 3:S165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/12\">",
"      Pacanowski J, Lalande V, Lacombe K, et al. Campylobacter bacteremia: clinical features and factors associated with fatal outcome. Clin Infect Dis 2008; 47:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/13\">",
"      DeWitt TG, Humphrey KF, Doern GV. White blood cell counts in patients with Campylobacter-induced diarrhea and in controls. J Infect Dis 1985; 152:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/14\">",
"      Smith KE, Besser JM, Hedberg CW, et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team. N Engl J Med 1999; 340:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/15\">",
"      Nelson JM, Smith KE, Vugia DJ, et al. Prolonged diarrhea due to ciprofloxacin-resistant campylobacter infection. J Infect Dis 2004; 190:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/16\">",
"      Gradel KO, Sch&oslash;nheyder HC, Dethlefsen C, et al. Morbidity and mortality of elderly patients with zoonotic Salmonella and Campylobacter: a population-based study. J Infect 2008; 57:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/17\">",
"      Jones PH, Willis AT, Robinson DA, et al. Campylobacter enteritis associated with the consumption of free school milk. J Hyg (Lond) 1981; 87:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/18\">",
"      Levy I, Weissman Y, Sivan Y, et al. Acute encephalopathy associated with campylobacter enteritis. Br Med J (Clin Res Ed) 1986; 293:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/19\">",
"      Karmali MA, Fleming PC. Campylobacter enteritis in children. J Pediatr 1979; 94:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/20\">",
"      Goossens H, Henocque G, Kremp L, et al. Nosocomial outbreak of Campylobacter jejuni meningitis in newborn infants. Lancet 1986; 2:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/21\">",
"      Sorvillo FJ, Lieb LE, Waterman SH. Incidence of campylobacteriosis among patients with AIDS in Los Angeles County. J Acquir Immune Defic Syndr 1991; 4:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/22\">",
"      Tee W, Mijch A. Campylobacter jejuni bacteremia in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients: comparison of clinical features and review. Clin Infect Dis 1998; 26:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/23\">",
"      Puylaert JB, Vermeijden RJ, van der Werf SD, et al. Incidence and sonographic diagnosis of bacterial ileocaecitis masquerading as appendicitis. Lancet 1989; 2:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/24\">",
"      van Spreeuwel JP, Lindeman J, Bax R, et al. Campylobacter-associated appendicitis: prevalence and clinicopathologic features. Pathol Annu 1987; 22 Pt 1:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/25\">",
"      Loss RW Jr, Mangla JC, Pereira M. Campylobacter colitis presentin as inflammatory bowel disease with segmental colonic ulcerations. Gastroenterology 1980; 79:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/26\">",
"      van Spreeuwel JP, Duursma GC, Meijer CJ, et al. Campylobacter colitis: histological immunohistochemical and ultrastructural findings. Gut 1985; 26:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/27\">",
"      Gradel KO, Nielsen HL, Sch&oslash;nheyder HC, et al. Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology 2009; 137:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/28\">",
"      Ternhag A, T&ouml;rner A, Svensson A, et al. Short- and long-term effects of bacterial gastrointestinal infections. Emerg Infect Dis 2008; 14:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/29\">",
"      Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004; 350:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/30\">",
"      Gerritsen van der Hoop A, Veringa EM. Cholecystitis caused by Campylobacter jejuni. Clin Infect Dis 1993; 17:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/31\">",
"      Wood CJ, Fleming V, Turnidge J, et al. Campylobacter peritonitis in continuous ambulatory peritoneal dialysis: report of eight cases and a review of the literature. Am J Kidney Dis 1992; 19:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/32\">",
"      Lang CL, Chiang CK, Hung KY, Wu KD. Campylobacter jejuni peritonitis and bacteremia in a patient undergoing continuous ambulatory peritoneal dialysis. Clin Nephrol 2009; 71:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/33\">",
"      Monselise A, Blickstein D, Ostfeld I, et al. A case of cellulitis complicating Campylobacter jejuni subspecies jejuni bacteremia and review of the literature. Eur J Clin Microbiol Infect Dis 2004; 23:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/34\">",
"      Roan JN, Ko WC, Luo CY. Abdominal septic aortic pseudoaneurysm caused by Campylobacter jejuni infection: report of a case. Surg Today 2009; 39:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/35\">",
"      Uzoigwe C. Campylobacter infections of the pericardium and myocardium. Clin Microbiol Infect 2005; 11:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/36\">",
"      Hannu T, Mattila L, Rautelin H, et al. Three cases of cardiac complications associated with Campylobacter jejuni infection and review of the literature. Eur J Clin Microbiol Infect Dis 2005; 24:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/37\">",
"      Hannu T, Kauppi M, Tuomala M, et al. Reactive arthritis following an outbreak of Campylobacter jejuni infection. J Rheumatol 2004; 31:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/38\">",
"      Garg AX, Pope JE, Thiessen-Philbrook H, et al. Arthritis risk after acute bacterial gastroenteritis. Rheumatology (Oxford) 2008; 47:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/39\">",
"      Townes JM, Deodhar AA, Laine ES, et al. Reactive arthritis following culture-confirmed infections with bacterial enteric pathogens in Minnesota and Oregon: a population-based study. Ann Rheum Dis 2008; 67:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/40\">",
"      Neal KR, Wright JM. Reactive arthritis like symptoms following gastroenteritis -- an increased risk with severe Campylobacter infection. Int J Med Microbiol 2001; 291:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/41\">",
"      Rees JR, Pannier MA, McNees A, et al. Persistent diarrhea, arthritis, and other complications of enteric infections: a pilot survey based on California FoodNet surveillance, 1998-1999. Clin Infect Dis 2004; 38 Suppl 3:S311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/42\">",
"      Bremell T, Bjelle A, Svedhem A. Rheumatic symptoms following an outbreak of campylobacter enteritis: a five year follow up. Ann Rheum Dis 1991; 50:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/43\">",
"      Peterson MC. Rheumatic manifestations of Campylobacter jejuni and C. fetus infections in adults. Scand J Rheumatol 1994; 23:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/44\">",
"      Jacobs BC, Hazenberg MP, van Doorn PA, et al. Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barr&eacute; or Miller Fisher syndrome. J Infect Dis 1997; 175:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/45\">",
"      Nachamkin I, Allos BM, Ho T. Campylobacter species and Guillain-Barr&eacute; syndrome. Clin Microbiol Rev 1998; 11:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/46\">",
"      Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barr&eacute; syndrome. N Engl J Med 1995; 333:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/47\">",
"      McCarthy N, Giesecke J. Incidence of Guillain-Barr&eacute; syndrome following infection with Campylobacter jejuni. Am J Epidemiol 2001; 153:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/48\">",
"      Tam CC, Rodrigues LC, Petersen I, et al. Incidence of Guillain-Barr&eacute; syndrome among patients with Campylobacter infection: a general practice research database study. J Infect Dis 2006; 194:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/49\">",
"      Kalra V, Chaudhry R, Dua T, et al. Association of Campylobacter jejuni infection with childhood Guillain-Barr&eacute; syndrome: a case-control study. J Child Neurol 2009; 24:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/50\">",
"      von Wulffen H, Hartard C, Scharein E. Seroreactivity to Campylobacter jejuni and gangliosides in patients with Guillain-Barr&eacute; syndrome. J Infect Dis 1994; 170:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/51\">",
"      Aspinall GO, Fujimoto S, McDonald AG, et al. Lipopolysaccharides from Campylobacter jejuni associated with Guillain-Barr&eacute; syndrome patients mimic human gangliosides in structure. Infect Immun 1994; 62:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/52\">",
"      Yuki N, Susuki K, Koga M, et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. Proc Natl Acad Sci U S A 2004; 101:11404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/53\">",
"      Fujimoto S, Allos BM, Misawa N, et al. Restriction fragment length polymorphism analysis and random amplified polymorphic DNA analysis of Campylobacter jejuni strains isolated from patients with Guillain-Barr&eacute; syndrome. J Infect Dis 1997; 176:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/54\">",
"      Goddard EA, Lastovica AJ, Argent AC. Campylobacter 0:41 isolation in Guillain-Barr&eacute; syndrome. Arch Dis Child 1997; 76:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/55\">",
"      Godschalk PC, Heikema AP, Gilbert M, et al. The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barre syndrome. J Clin Invest 2004; 114:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/56\">",
"      Koga M, Yuki N, Kashiwase K, et al. Guillain-Barr&eacute; and Fisher's syndromes subsequent to Campylobacter jejuni enteritis are associated with HLA-B54 and Cw1 independent of anti-ganglioside antibodies. J Neuroimmunol 1998; 88:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/57\">",
"      Ma JJ, Nishimura M, Mine H, et al. Genetic contribution of the tumor necrosis factor region in Guillain-Barr&eacute; syndrome. Ann Neurol 1998; 44:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/58\">",
"      Yuki N, Takahashi M, Tagawa Y, et al. Association of Campylobacter jejuni serotype with antiganglioside antibody in Guillain-Barr&eacute; syndrome and Fisher's syndrome. Ann Neurol 1997; 42:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/59\">",
"      Takahashi M, Koga M, Yokoyama K, Yuki N. Epidemiology of Campylobacter jejuni isolated from patients with Guillain-Barr&eacute; and Fisher syndromes in Japan. J Clin Microbiol 2005; 43:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/60\">",
"      van Duin JM, B&auml;nffer JR, Nuyten PJ, den Boer H. Comparison of Western blot, counterimmunoelectrophoresis, complement fixation and enzyme-linked immunosorbent assay for the diagnosis of Campylobacter infection. Serodiag Immunother Infect Dis 1993; 5:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/61\">",
"      Ruiz-Palacios GM. The health burden of Campylobacter infection and the impact of antimicrobial resistance: playing chicken. Clin Infect Dis 2007; 44:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/62\">",
"      Ternhag A, T&ouml;rner A, Svensson A, et al. Mortality following Campylobacter infection: a registry-based linkage study. BMC Infect Dis 2005; 5:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/63\">",
"      Ternhag A, Asikainen T, Giesecke J, Ekdahl K. A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused by infection with Campylobacter species. Clin Infect Dis 2007; 44:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/64\">",
"      Lariviere LA, Gaudreau CL, Turgeon FF. Susceptibility of clinical isolates of Campylobacter jejuni to twenty-five antimicrobial agents. J Antimicrob Chemother 1986; 18:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/65\">",
"      Kuschner RA, Trofa AF, Thomas RJ, et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995; 21:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/66\">",
"      Sanders JW, Frenck RW, Putnam SD, et al. Azithromycin and loperamide are comparable to levofloxacin and loperamide for the treatment of traveler's diarrhea in United States military personnel in Turkey. Clin Infect Dis 2007; 45:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/67\">",
"      Tribble DR, Sanders JW, Pang LW, et al. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis 2007; 44:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/68\">",
"      DuPont HL. Azithromycin for the self-treatment of traveler's diarrhea. Clin Infect Dis 2007; 44:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/69\">",
"      Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/70\">",
"      Gupta A, Nelson JM, Barrett TJ, et al. Antimicrobial resistance among Campylobacter strains, United States, 1997-2001. Emerg Infect Dis 2004; 10:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/71\">",
"      Ibrahim NG, Zafar A, Hasan R. Evaluation of frequency of isolation and trends in antibiotic resistance among Campylobacter isolates over 11 year period. J Pak Med Assoc 2004; 54:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/72\">",
"      Prasad KN, Mathur SK, Dhole TN, Ayyagari A. Antimicrobial susceptibility and plasmid analysis of Campylobacter jejuni isolated from diarrhoeal patients and healthy chickens in northern India. J Diarrhoeal Dis Res 1994; 12:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/73\">",
"      Engberg J, Aarestrup FM, Taylor DE, et al. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis 2001; 7:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/74\">",
"      Hoge CW, Gambel JM, Srijan A, et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998; 26:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/75\">",
"      Rao D, Rao JR, Crothers E, et al. Increased erythromycin resistance in clinical Campylobacter in Northern Ireland--an update. J Antimicrob Chemother 2005; 55:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/76\">",
"      Gaunt PN, Piddock LJ. Ciprofloxacin resistant Campylobacter spp. in humans: an epidemiological and laboratory study. J Antimicrob Chemother 1996; 37:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/77\">",
"      Campylobacter Sentinel Surveillance Scheme Collaborators. Ciprofloxacin resistance in Campylobacter jejuni: case-case analysis as a tool for elucidating risks at home and abroad. J Antimicrob Chemother 2002; 50:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/78\">",
"      Rautelin H, Renkonen OV, Kosunen TU. Emergence of fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli in subjects from Finland. Antimicrob Agents Chemother 1991; 35:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/79\">",
"      S&aacute;nchez R, Fern&aacute;ndez-Baca V, D&iacute;az MD, et al. Evolution of susceptibilities of Campylobacter spp. to quinolones and macrolides. Antimicrob Agents Chemother 1994; 38:1879.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. Enrofloxacin for poultry; opportunity for Hearing file://www.fda.gov/OHRMS/DOCKETS/98fr/103100a.htm (Accessed on October 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/81\">",
"      Nelson JM, Chiller TM, Powers JH, Angulo FJ. Fluoroquinolone-resistant Campylobacter species and the withdrawal of fluoroquinolones from use in poultry: a public health success story. Clin Infect Dis 2007; 44:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/82\">",
"      Vlieghe ER, Jacobs JA, Van Esbroeck M, et al. Trends of norfloxacin and erythromycin resistance of Campylobacter jejuni/Campylobacter coli isolates recovered from international travelers, 1994 to 2006. J Travel Med 2008; 15:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/83\">",
"      Centers for Disease Control and Prevention (CDC). Campylobacter jejuni infection associated with unpasteurized milk and cheese--Kansas, 2007. MMWR Morb Mortal Wkly Rep 2009; 57:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/19/19769/abstract/84\">",
"      Jagusztyn-Krynicka EK, aniewski P, Wyszyska A. Update on Campylobacter jejuni vaccine development for preventing human campylobacteriosis. Expert Rev Vaccines 2009; 8:625.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2715 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-E943584887-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_19_19769=[""].join("\n");
var outline_f19_19_19769=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2644129\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2642806\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2643607\">",
"      HIV coinfection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Unique manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pseudoappendicitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Colitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2642663\">",
"      - Acute onset",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Late onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Reactive arthritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Guillain-Barr&eacute; syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Choice of drug",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2644129\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2715\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2715|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/36/38478\" title=\"figure 1\">",
"      Timeline of Campylobacter enteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2715|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/43/35518\" title=\"picture 1\">",
"      Campylobacter jejuni colonies on CAMPY agar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/34/14895\" title=\"picture 2\">",
"      Gram stain of Campylobacter jejuni in stool",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2715|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/45/9950\" title=\"table 1\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/58/19368?source=related_link\">",
"      Infection with less common Campylobacter species and related bacteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=related_link\">",
"      Intussusception in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/60/5065?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of Campylobacter infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/42/2723?source=related_link\">",
"      Patient information: Campylobacter infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=related_link\">",
"      Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_19_19770="Cervical ripening balloon";
var content_f19_19_19770=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 597px\">",
"   <div class=\"ttl\">",
"    Cervical ripening balloon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 577px; height: 676px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Cook Women's Health.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_19_19770=[""].join("\n");
var outline_f19_19_19770=null;
var title_f19_19_19771="Equipment tube thoracostomy";
var content_f19_19_19771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=14\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=14\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Equipment list for tube thoracostomy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        &bull; 1 or 2 percent lidocaine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Needles (size 25 and size 18-21) and syringes for anesthetizing the skin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Scalpel, with No. 10 or 11 blade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Three Kelly clamps",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Straight scissors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Chest tube",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Silk suture (1 to 0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Needle holder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Petroleum gauze",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Drain sponges",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Elastic tape",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Sterile drapes, gown and gloves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Mask, protective eyewear",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; 2 percent chlorhexidine or povidone-iodine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Drainage system",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_19_19771=[""].join("\n");
var outline_f19_19_19771=null;
var title_f19_19_19772="LD advocacy file contents";
var content_f19_19_19772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50005&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    File of documents that parents maintain when seeking special education services for their child",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        A copy of the child's school records, organized chronologically",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A summary of the child's medical and developmental history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A copy of past diagnostic evaluations, including IQ tests, achievement tests, and tests of memory and language",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Copies of state and federal special education laws",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        The telephone numbers and membership lists of local or state chapters of:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        The Learning Disabilities Association of America (",
"        <a href=\"file://www.ldanatl.org\" target=\"_blank\">",
"         www.ldanatl.org",
"        </a>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Council for Exceptional Children (",
"        <a href=\"file://www.cec.sped.org\" target=\"_blank\">",
"         www.cec.sped.org",
"        </a>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Children and Adults with Attention Deficit/Hyperactivity Disorder (CHADD) (",
"        <a href=\"file://www.chadd.org\" target=\"_blank\">",
"         www.chadd.org",
"        </a>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        National Joint Committee on Learning Disabilities (",
"        <a href=\"file://www.ldonline.org/njcld/index.html\" target=\"_blank\">",
"         www.ldonline.org/njcld/index.html",
"        </a>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Information related to special education laws, advocacy, and advocates who can assist the family at the admission, review, and dismissal (ARD) committee meeting may be obtained from the following organizations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        The Learning Disabilities Association of America (",
"        <a href=\"file://www.ldanatl.org\" target=\"_blank\">",
"         www.ldanatl.org",
"        </a>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Council of Parent Attorneys and Advocates (",
"        <a href=\"file://www.copaa.net\" target=\"_blank\">",
"         www.copaa.net",
"        </a>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Families and Advocates Partnership for Education (FAPE) (",
"        <a href=\"file://www.fape.org\" target=\"_blank\">",
"         www.fape.org",
"        </a>",
"        )",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        LD OnLine (",
"        <a href=\"file://www.ldonline.org\" target=\"_blank\">",
"         www.ldonline.org",
"        </a>",
"        )",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_19_19772=[""].join("\n");
var outline_f19_19_19772=null;
var title_f19_19_19773="Sample schedule for laboratory tests after lung transplantation";
var content_f19_19_19773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F83298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F83298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sample schedule for monitoring laboratory tests after lung transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Weeks 1 to 4",
"       </td>",
"       <td class=\"subtitle1\">",
"        Weeks 5 to 8",
"       </td>",
"       <td class=\"subtitle1\">",
"        Months 3 to 6",
"       </td>",
"       <td class=\"subtitle1\">",
"        After month 6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weekly",
"       </td>",
"       <td>",
"        Every&nbsp;two weeks",
"       </td>",
"       <td>",
"        Monthly",
"       </td>",
"       <td>",
"        Every&nbsp;three months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CBC",
"       </td>",
"       <td>",
"        CBC",
"       </td>",
"       <td>",
"        CBC",
"       </td>",
"       <td>",
"        CBC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potassium",
"       </td>",
"       <td>",
"        Potassium",
"       </td>",
"       <td>",
"        Potassium",
"       </td>",
"       <td>",
"        Potassium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnesium",
"       </td>",
"       <td>",
"        Magnesium",
"       </td>",
"       <td>",
"        Magnesium",
"       </td>",
"       <td>",
"        Magnesium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucose",
"       </td>",
"       <td>",
"        Glucose",
"       </td>",
"       <td>",
"        Glucose",
"       </td>",
"       <td>",
"        Glucose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BUN",
"       </td>",
"       <td>",
"        BUN",
"       </td>",
"       <td>",
"        BUN",
"       </td>",
"       <td>",
"        BUN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Creatinine",
"       </td>",
"       <td>",
"        Creatinine",
"       </td>",
"       <td>",
"        Creatinine",
"       </td>",
"       <td>",
"        Creatinine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AST, ALT, alkaline phosphatase",
"       </td>",
"       <td>",
"        AST, ALT, alkaline phosphatase",
"       </td>",
"       <td>",
"        AST, ALT, alkaline phosphatase",
"       </td>",
"       <td>",
"        AST, ALT, alkaline phosphatase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lipid panel*",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Lipid panel*",
"       </td>",
"       <td>",
"        Lipid panel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Amylase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CMV PCR",
"       </td>",
"       <td>",
"        CMV PCR",
"       </td>",
"       <td>",
"        CMV PCR",
"       </td>",
"       <td>",
"        CMV PCR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ImmuKnow assay",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        ImmuKnow assay",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        ImmuKnow assay",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        ImmuKnow assay",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"4\">",
"        Drug levels",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cyclosporine trough or C2",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Cyclosporine trough or C2",
"       </td>",
"       <td class=\"sublist_other\">",
"        Cyclosporine trough or C2",
"       </td>",
"       <td class=\"sublist_other\">",
"        Cyclosporine trough or C2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tacrolimus trough",
"       </td>",
"       <td class=\"sublist_other\">",
"        Tacrolimus trough",
"       </td>",
"       <td class=\"sublist_other\">",
"        Tacrolimus trough",
"       </td>",
"       <td class=\"sublist_other\">",
"        Tacrolimus trough",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"       <td class=\"sublist_other\">",
"        Sirolimus trough",
"       </td>",
"       <td class=\"sublist_other\">",
"        Sirolimus trough",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The above table is a sample monitoring program. Each transplant center develops its own routine regarding the specific tests and their frequency. Some patients will need more frequent testing due to symptoms or prior abnormal values. CD3 cell counts are monitored initially following induction therapy with a polyclonal agent or alemtuzumab, but not on an ongoing basis.",
"    <div class=\"footnotes\">",
"     CBC: complete blood count; BUN: blood urea nitrogen; AST: aspartate aminotransferase (formerly SGOT); ALT: alanine aminotransferase (formerly SGPT); C2: cyclosporine level two hours post dose; CMV: cytomegalovirus; PCR: polymerase chain reaction.",
"     <br/>",
"     * A lipid panel is assessed monthly for the first few months and then every three to six months.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     The ImmuKnow assay is not used by all centers. The frequency of testing depends on the given center.",
"     <br/>",
"     &Delta; Drug levels are guided by the individual patient's drug regimen. Examples are given in the table.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     When monitoring cyclosporine, trough levels are used by most centers, although C2 levels are felt to be more accurate.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_19_19773=[""].join("\n");
var outline_f19_19_19773=null;
var title_f19_19_19774="Control of lipids decreases the progression of SVG disease";
var content_f19_19_19774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aggressive control of lipids decreases the progression of saphenous vein graft disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 319px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the Post Coronary Artery Bypass Graft trial of 1353 patients, aggressive treatment of low density lipoprotein (LDL) cholesterol with lovastatin and, if needed, cholestyramine to achieve an LDL &lt;100 mg/dL (2.6 mmol/L) reduced the progression of saphenous vein graft disease, regardless of the number of coronary heart disease (CHD) risk factors. All of the differences were significant except for an almost significant trend in patients with no CHD risk factors (p = 0.07).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Campeau L, Hunninghake DB, Knatterud GL, et al, and Post CABG Trial Investigators. Circulation 1999; 99:3241.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_19_19774=[""].join("\n");
var outline_f19_19_19774=null;
var title_f19_19_19775="Rx NB testicular torsion";
var content_f19_19_19775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75762&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Recommended algorithm for management of neonatal testicular torsion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 304px; background-image: url(data:image/gif;base64,R0lGODlhTgIwAcQAAP///8DAwICAgEBAQAAAAPDw8ODg4NDQ0KCgoDAwMGBgYCAgIHBwcLCwsJCQkFBQUBAQEAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABOAjABAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY4wBgGSk5SVlpeYmZqbnJ2en6Caj6OkiwILA6mqq6ytrq+wsbKztLW2t68Epbu8ggICvTu6wcTFdb/GN8PJzM1oyM4yy9HU1VvQRZJbCAY0BQ7AK9ok09bm51HYAKkLqAMrDAciAwEs6ivvMfcs9CT9LAgQzKs3wEGDfSTulUPHsOGRfdC+CegGIIAABwUKJHBQ70ABABLl1QNgoBuyA79G/3o8QJEkgQDyvmEUUS9AAQO/upUUgWCiCJYOZpLwCDJogpE9RwbAKRCAAgU2PRp4yZJi0hE9FYQbsdCh1689IAIrMABBgwQGzgYIamCB1nU2NzZ4AGAYMmQGAxxdl6DsiAAEBCAosCDggo8EUjVY0AABAwDIBghQu+5Bg7f+4ppdUE9rgAEN6jLQS1CyAXqABSPzDBrAAwGft4roCra27RliASB4IEmrgwct/9FDoICciLvhLEpe19S47scAGAgk0O3AAnnHJyYQcRluxXwjhheH21aSg3d2gUHrl7782gFts5egfbu+/RS5BUhOWUBAAgihCWeRbOlBJoBGo731j/9z0CCzDAIDBGbgZzS90w+Fma0nyQK/CFaXfBp+OCGHvyCAoUL3pagiCrlBOEJG3Fk40nD5IAYibPlENpJzc4mgQGjDfASSLr8UAAFPj10I3kDEDWQABELaaOCU3rUHpQg3LSCfcyt2qWJuTkn2QFCSJSCQfkkSpNV2CjygQALqHZgAA28Cs2B4CjiwzlP5DGOdAG5OiSZa3mEYXlwMMMCZbhw+JSIyAXB4AHvyIdBocW0ysByXXnZ62z47iRAJRaOOcIA8RAFwwI5L7bRTAa1WJ2QJS/2EXUUvwiQqqTsSVcCtPwkZVZS64koSr6p+NFKosN5aVUuzeSqtbQh9Rd//tNhSU61X12brbTLbOtTtt+T2Em5D45ar7ijnMpTuuvCa4g4u9NZr77345pvKu/H2a0gkoQQscCgbDWzwwZn4q/DCMtzJ8MMQt+FwxBRXPMbEFmescRYYb+zxx090DPLIJBchcskop7zDySq37HIMLL8ssxX61mzzzTjXAkFfOffs88/3ztzISwgXbfTRSCet9NJMN80Jv0L3AXXUb0xNdR5WX71G1lrXwXXXZ3wNdhxijz1G2Wa3gXbaX6zNdhpuv71F3HKLATDR0Nadxt2S5K33HAgQILjgzf2NRuCDE1C44XJMlbjfjI/h+OCQR+7GAoNraTkamAuu+eZyKDA4/3Sgl8HA4OOVDkcDg4emOhmsC+76624UMPistINhu+C4575GAgRs57sYwAs/PBuny3Z8FwIQQPryaQC2I/RcSE/91te3nb0ai2+PRffehy/++OSXz8KqTqev/voBA4sO+uzHL7/S7ts3AM9A56///rb05dX9/AugAHPmvxXFzD6GYsgBzZHA+yzwNg08xwOrEcH6TLA2FbTGBaORQdts8CsdpMYHmxFCsIyQDdzIQgmdccIzGAB8Sljh/6ZXhQBA4H7Po0FAUNDCIciQGT3UwSnuB0MS7LAFB8jhX5bUhB82JIhBwNCYfgWrovikIkwRFTia8pSopGQgKmSiBGnIBP9kEEYePSFVTpwClZu80CcF6MlMEHAUA8TxIsoS4xKcqEAyTgFDDIDNAvpCFrMQynmkAUBjAqAg0+RlL1AEAh+LEckbQOMoklFLWxqTJNP4BwHnURVHQnkK2BxglO+YpCT1eJtK+oA0lopEAj6ym94Ao0CiVMA7sKEcO/lRCqoMhitrIACo+McAwruMdW7VoHAM4426MBQ0vxOFYGrwl9XkkAO6caL9wOZRwGhTA0g5ljkx0pdhnGE6JDMYDFEIQhJqZrToaKJo5oOegKEmFKxZjWHyIIEYchGWwCkiCkEqR+jEAj934U/cbMVISIoSkcIBDV38w55g/NBCd7BRFmL/c59LMpQuAaWnAmUqFRXhkF7oBCfvKJSV/fzoQ2QzKAP8KVCREgBKnKkbOD1AF0aaDB0BhVGQdqmhOvgVCZQ6glIZK1QwYWokQBKrZKXTIUiNQaiauqNmcfVYNPlJTbBkE1WNlalP6GgzspoMtT6CrY1wazLgWgy5NoKui7ArJWV6H70uAq+K8KswaXjKE4xjCCn8C1+bWkQu9Kd3gk2Ewx4bhMTSZLGXLQNlSRBZXjgsAfWj0hDupI4GJrFCRDhgPDK6giZxFqYipKECGosD0srGtNBpFw7eBZ53uXaJR51eT7ToIQP15CO/ssiO0hisZx03i6r6okuzc1yQyKMk/zal41I+o1wTWEQgVaTJTba4q+cWlyhLOe8XNcIRq8pEWNBdB7Q6e4g7nQZLq/pmUYSyEuyatyk7ndH0SnQg6x4ru3UksN++S9W//Eq6QNFTd3GVXP0exCdT0dWyilvhHcHntcH1h5AW+Rb/jHM7OV3MRzIJyb70xEwOMOdeHkmQASfgxNT0z5xKuaHJHMaIvEmUUx5DJ0WaqMQwlnGNRZNIGrdFQTYpjKUQM5q9KPK2sI0GaV2X4sMQxjArdvEnY1zletB4upC5cYxznIAdq3TMTKylkBVA5OKceQCWaZOPbdTlj4xGxamZTkVurJ+U7pk7WA7xCIyXy12GA7QYov8HMrlTHL9QCZe9RPMlV7XL8bgzH3dijCSAOqdZ/sQBury0fChFpUwLyDEikA5BQRLSLHtUxKiFC6yjIxBLV3RLrh7wozkNGU8jNFokEHU+EWTqiugHnZGuR1H7UYCDLGoZuviRCNASbSzVWtHzGIE4yTmQaH/apb82EILOqelwoMbRue42VzqUHAJgZ9zwJiiri2ROKA9EnrhcB4ixOj3wRFue/0g3vxOU0C29u9XHFtG8O0QTe4Ok39AGtbT1SQ/rcGQv2Hbpw6f7bQMWnCuohQaUog3R56CbpxM6tm1FsPJ8nxvNiwLJxf0jJYPCXEfgPFFC6dEjpwBpSwWgC3D/CU6CBwhL40XXdsJ/jqNVC5vmsLJ5xMuRc+TCaZZCL5TGNarxEIWcAXoCwGHknfSBq+hOwPHRAzS1Sw4tp9s1fTmyF14nTdsdGD7HEgQmI++fLCBRbAJGkU+a7wLtW04sVc8A0rSnVM8alG7vIwkc0JRuD4BPGVU45PtO2r/nOBxBvTCyTXV4BiQ+OgpAEOlrMvZpw4RDD1jU50tKkjndfey6SXuu3z49Rv5lJceqlYGtSpJeCQmqu6Iqdpm/K+Urdauwygh2UsXZeoS3IspCPvTBit7ow2r6qkKVkE71l+gDoNnD1/yLhMfUVLE/WO5fVjfOvxPuJ58i19cS2Td+/7TifaySEVXlK9unLMtHFJFARTTBTX8BgAu4bbhDX6XgMJZWG5ixdE9EQ8VkDR0Yfw5EQ9/3FSdIgmPkXb2TDCmoT8SXLRhYCICVCDM4CjXICzc4CDl4CDvoCD1YCj8YCEFYCEPICEU4Ckf4B0k4CEuoCBGSOFI4hVRYhVZ4hViYhVq4hVzYhV5ohba2Vl84hmRYhmZ4hmYYhqVDN+ajA2zYhkTwhnBoA3I4h0BQh3YoDXnYBXi4hy/Qh36YA4AYiCswiIRYA4Z4iCeQiIoYA4zYiCgHiVHAN8oniUBAiZVjiUWAOINDW5pYA5xIOJ+4BJMjOJk4ijVQitSBikrQOf8E8DmsuAOuCIuxWASiIzhKVIs2cDqCkzq6SASxQwCz84s3EIzDSIxBsDsE0ILIKAPKyIzN2APFE404MI3UKATJc4020Dy5qI06YD3eOAPgGI4+8IiSaI7E6InkiALquI7u+I7wGI9WMCkDVI9AE1oKQ3f2uI82040bQxrzE5BMY2URUxACeZBHE0oo84Rm0IQx9QgMCUFqyIOYVS4OGQYRaRsZeTEVSS4XCQYbCRYhGQYfeWsvIkeniAJolQKnFQQTuZIsMJJeYVq69ADtSAIvFJMTOQNAhY9SdZOsBTF3AidrQYtI5I8e+ANF5V350JIuIJMOkUCE0RFKBwmeSF//S0kr+ZCTMFCSa8Uq4PERXJlCCHBKNoEmAsGV+qEALFGTIsFEB/AABUESutQUZvEAcReXdzcSPMVjBuCWkKFSOdkfkqEsl3EnUNkQAMVoqgIdqyUdNnkaqfAYp0UW99MAB9AXZgKDPNFmdHEWCRB70aEpi0JH/nNEfeIUN1SWmikQCrCap0WPA4BGpCl8QfkwC2Iko/F0YDQAKhVIupFK71BkB9AANqUqWpJAbeEResIZSddrDPANxQEBzKlqH6JdJYEqWoKdFFJixaEfNgWLickQDdRmk5FHvSlplkFNFDIm+AcSR5JA1vER8vBjF8EcikQXy6gq1llUURKf+dCe/zVBFyHYcodSMfalHxBQHJ43EldCIRRyJVihS1npAKQzKTRBF0qidrvZnzBIHBGiTxE6AkeSbir4MRFkEQ8AdmN3UahFIdNQALoUognESwEqI9S0ot+Ubv45o0UFoyhnorfJMB3DGQ2KbBCKHiRAJ92QlTaKWhv6DQ8AJTyqT0xKdqgVckI6nujQQUdxpAUlnHUxK+6JpSMgABcqPAGgobR3ahCAEzBXVGX6o+8goSUKcwdKMQuyKliyADa1HRqxZO9XDw0gppY2KaExFZwZKT8BAFdynxs6EkdhoS4RLXoxD4kaTWr6Duu5ptZ5oh4DUD4RKVkCK7o3Eu5ZaN35GP9p4Z6Bw5lP0g3NaRM2KXaQkRHXsRu6MQy6YB0g4aq9qiVZ5xTq8Z14OqQLsyAGkHuXKQIruqKCmpl4KaayiZmocDqcmWZ4pkhtJpobuqJzAhLXyqvzUBbWMXnDkAom8g6yKQ9bupMPI5Xn8XkUcR5oKg+rBRJ6xq6PQZhsmXSgwa+0Ipd68peWtlqnNa+uo0uFGm6QARoA27APi5n9+my01BRM5JVA1JElICS/JQdceg4LxRLRoTxxoLFzxbFG5A7Q2AYhy0DwqpWbUgcoaww1qwUvaw05iwU3Sww9+1Ips7NX8LO9QLRWILQcFLNFUA6WFQ5z8XkqWwNGy1BRywf/SOsMIVsOC6Kp3dAASNkDU5uBaDi2ZFu2WKi0CvODrpcKfkaaI/EmIZoZQfq1QBC2EIOOZvODQoJ2+NkjlCpxrKULT/IaVUsDdvsweDs2P1iovplxLqW1OxIkBxGaR3C4DJO4YLOD8zklG+qicjskHcuIlrswmNs1mnsYp+G4v1ERTOt0xQYAnPcRCmkyhcs4pas1PwgheSIQCJtbAWsCEFKYJEF3BWYEo6swt3s1V0sFx+svyUs1yzsFzdsvzxs10SsF0xsv1Ss01xsF2Qsv2zsz3QsF37su4Ssz4xsytWs45/syAImQ8HswBLk97esyssmPsZAY+CsL+Lg89auI//9LPgFMiAMsPgXshwfsPQmchwucPQ08hw9MPRHchhPsv/LohhfcAhVcPhs8PB08Ph+cOyHsLcG7v/qivyacL0AZDSWcwveCwi5sL9lSTPFbwzZsS/VBwze8wwc5wnOgW+YAxNUgxNXgw3JAxNpisl6BxNFgxHHAxM4AxcwgxczgxHBAxeCixA6BxcZgxW/AxcUAxsEgxsHgxW5AxuaixQ2BxrxgxmvQG1BRViDESHEsknQsCS1bDZjYKVF4O2ABAYljlOjQx7zzFaGoOJ3SPIPDmA3xU6gDFoosOGgbDKqYkrVxAImjxuYQisdInplcG7MoLYAsOOvLC6WYx9Ywyv8vwYGP7CmO7MZe0DmM3MiCcyS1YYzSgjhVCRa3qMnm4ACCs8te8YzS4ji2+RWxU8qmLDjH7BXWKC2Y07/osDv1gTmWbA3N48v2oQCC7MzC/BXcXB/j6CndUR98exsfWxuwvAbVZh/3ZxvtXB8rnMH0XM/2TDH3G8P0Ms9V0ML6jAv8PAX5/M+2ENDSS9D1Mgfvy8OgMIJjoMMM3dDajLNfGtGf4NBiQDQW/QnrDKpewMZLANJJINJIkL5nOtFaEMIdna1hQNJI4NJGANPZMMnpgNJZoNIKTdNQINNFwNND4NNCYNJbUgY4DbI6/QRALQRJDQRL/QNCLVpkUNRxsEL/W8GVJZCTCOF/LsAyTf0DQjwgV5RCXQGTLeBEXd0DVM1YJ4DVSqzVLcDVNo0FUNMhTcHWJ+DW/FCRK71Cy1BBdm0CGwTXZyDENNwAb6obTWpYMWvWcX20ttbXevTXJRDYMnXWPQA1ROMokv25XanXOc0CkP0cvqknp4UMazsAv7Iz7MozfrYbjsHaaHYCls0DhO1u+CoPvdqaqukXrreZSaQfmUlELI0fjV1Djw1cjjHajTklp53a/hPcqM1rNtncsW0Csy0MMDAMnlraisfaB6DaqgLbkPnabFvdKbDXx51yxQFRgbe3evIPP9YkqbAU7m3eCVHcVUDYkmF5lPKf//oEDiLgpzbEEf7N2GbA18BVoAA6JfUN37RUaZLW4JWN31SA2b+wKO0da+89EvEN4fSt4fa9iJ9diAnOU4HHuBxSKDcEQC6F4g3HIhQ+BYQdx8vR3z7KcTwDAZJQIzdu4GWA4Cln4vDm4iqeCv7zD0Qu2GaA2ZKAADU3JUleEyt+5CMR5X844iqwDA37az63uUB3qXLr5S8u2zEuBbUNpRs3pxw3jFKUdlm5AtedA0CuSI13emJeKIzZD3eu5ESd3YfS5fYJbXneEYEe4iaA3izwFs+paoB+E8thkx+xESTRa4Tu6GNu3WVe0y9gRv6mC8CKnCBxFl1LbK6hJ6/q4/9ksEKKXqtc7mjzmbquMRjvV7CUjpyWbuhQfTZ+nlLD+guv/uiyLuk5qeeoW+OebdQsQJiWhprLvUO6y3mqgpcgoSnrma/PzrvSnOtiIMQlnHar9Q4RmyOt8bTR2ZLhvtwuEOc4sELKbpcY2+wCce3RThcFQO2hYe27h+1wnulQADWqwJbwHpy7O+/Tjmf3jh3ynq8ajOUPze9I7fBNoO438NQSrwxhw/DbDvERr/EhzfExdNROUPF0ePHIXgYiT0weP9IpX9Igv/Ek3+clTwYnTwMzLwM1HwMUv/JIINVw0ECH1dlCQNY3rw/KY1m7noz1M/Qv4PNRy1ZCr/NHUA7/Vg0DGOjWiN59M8BWEaT0m17013zoPiRGXF/WTPTzL6D1Yg/1RiD1/IyBE3P1WMG7bksW4VFt3bpia2GXpt5mlNkmoQkhi2KZoCXaC6Anr7mB2t7SyvPtpAkr0HEA32me0QLw0VEPvS0QkL+is+Wb3mfk+Oq2u104Y6+TJbBDicL5dD8Pdh+aeA/twRcdbYb5fr/5ge/5hG/4q3nfL/8Tj5Hche8U2DEa7fodqb8OvyLebvusnRmu69D4311AkTjVTBQZAtEj4/4O9rnhYH4UGOoUJmJqm9kjvEESWqLgLD369qA87NENaGckfqZToIbbkNGvUALgaidLkV79dDH+//EBAgMCNA8QDIC6CsL6wrE807Uto3ALiKQ5NEipRQEgcPACgYQqEXC4AAvDspgYlQCPAMCwMCoABcgppYve0ur1mgDLCcJjI0MMKWxPphxQKC0ihPU0JFgdHJgpjBAYADAgDXDBuLFVWl7e5LzsRJYBIJg8NGjycS0cMgksDAwsCGh25hCwDrjtALhpbqJh9vqewXRS7igg3d3uuBmQOdQNJLBCKJnFpsyyulV7Av92++qqcHLlgGqNmpVKofJAD0jDjlvT2kblmu1652NSrsDVdzGrw8/ep1CjILCClmRbJFWsXOEK56LTJH0WLYIzMjGeilNfDjDRszAQgxEC6v/0o8aRQBEW/zJqvCjzxq0VwiR2WdAgTLNwSCgpStCoT0oV2li+0Aaz5symLzKK2+YRAEgVAX5wITmCqFWVnpC6VEGQm9OyYt+kuAUUgVAAd1SQ0TR1STCOSU5WjEnxBT+zfmlA3bhNVZQFAfBs5VJgAZGcXA6cM8qRgYICBZCopfqlJc6/TpkuHBalFRcvBkxHPLFKBaFGDQ7A80TZMiSOBzbj8zwz8EJNhDsefpBYDOMirUnA9ppj9uWYEW+Lya1bZl9PmVUnchFnMEQACZAYGA7Py+MgorUg4Hx2OvttKxCMYHCAKkoDA1oaUNDD0XwjSFQcoJ8Ch6AkH30qOMD/ChLwGRUOV861pw9oBprBIAlhWPVAHjyssKEPAzBQwAEFzjciggryd6ARD4IW4Tf3qMCggSZ2cZ8K+e1noH8rlACiiCSqmOAAC47A4YpBhOViPtWZaOE9GxYgwAACFEGjfS0VwMAAoqRI44wCzlfhCAdomJeSfsF0piUtqrkmL226CWcvacqZBpt1plEdnmrouWc3dPo5w52BCvomoTQMeuhTMCpaaKM39PkoX5K+SKmjlsqQ6KOaNgqopJw2GqmlomJag6ebGloqqIeuSuipjbZKKKmSzloqDoyqmiqmsfrJ656vKurrnrWGamslwLKqq6XC1smsnMgS6qycxCpK/62xVrnSgrbbctutt9+CG6642055LQtTjpuuuuuuW665AWTLrrzzyuuuuQTQm6++4lp7rQH7pssKwONK8u7A4gp8MLgFG/uvwt8m/HC3DBsr8bf4WtytuXJKu3GzynpMaccht9kvybaOfLKSKavcHssts2cyzJ+CPHOgL9vsF845myUzz9HW/DPHQQut5s5FU4f0xkcrLSHRTbv8NNQxT42y1FV7xjTWmGi99SU+e82eEgoooIR6YU83dtkUo+2Z2ma3zR4VARCgRCNx41kLAXuDhbdnEPBNwBd+e6Y332cT3hQCgRNQZOJGBx7S42Y9EDiGk38WOK6YW2QA43dzHv/hAYFfHXoli/ONpOkX0c136aursQDfg8POHuB7s137L54frrtFt9ftuz4K8H258H5Vvvfx+shOgOTL+5I8GdD/0kDq1JuFugnY+0I8vtz34sDe24NvSQG9ly8T7/+lX4n1wbfPxvrxV5KA8/RfJHt/+KdxPtjpyw50/LOBAL43QG8ogHYHtEECyLdAGiTwgTagW+4kuIadWLAGj8jgDALBwRn8L4MFUN0HX3CIEsJghCiEgeNW6MIXwjCGMpwhDemHgIzhMIc6BBcNbrjDHwJRYi08QxCLaMR5CfAFDjsiE5sYriSuYQAKcCIVq1hAGkjRilo0on5ogLEtglGHhpn/AbzCaMYcjvESe1mgqNY4QECFsHZuLIoE56gGO+KvjRWMHxzrWEFoYQ+PNxBk/PQowT4+EI+ApB4ha9DI9BnygYhcoCI3h79HzsCOdntW1/4SyQVOMg2IoAVK2hMAAUDxUJW0ICZl4EYEAM94LqLbKhAxxDPZMk9Y3GOmSOciLWEqlJkgAEJAZML5FOAwK6BCKq2SRNicLQB3KyDbksnLFCrzKde0xCrZwDgX5dJSrYzBGkfXGAwGoD/ppMpjinDKUfTHYciUpoigyU71NKAF6SkA8RxgAPGV7UYtmKcBRGRCaTrAAfgZKI8EkB4xSDOfkjhAC/wJAIBKQp4x+KSd/2bRgsdIUwBBuCFnbvhQ2FDFnSJdZxcYeoJDOLQL9pPmCwpwQwfMh6Xr3GmMXkHTExyhEcksKGwkoQQ2CHOCs9iE8/YmAMCFhAHFMwIBEkgl+/FNDIZbxAJuNwq+wUh8WV0qLlJQCwZI4wDAS8Ft9gYB2BDgAdCQahDsh7hdktGSXvwiRMNDpX+pTqNDNehlHAC3Tzi0CMy8YSMwCgOKirQAVFDsYSZ7mpYi4KhigAKSUHoAKsxzf2kYZ11MSEwGNKAlZF1qLWa6uFUsdXEJkN1X7TekxklheiuYhW1bh6/AfcJ5tKWbbZNCzL2lQLa0BQDx3FEIugGPC8+oxR2Aq/9cApAwNa7cJlPXVgTqIhe5YkgAQu7X2rq9thbJFS52cQG8FrhuBYtByGpWa42uuoF4CbCfC5oLAQhQoalbYoTnHJgJvfbLt98rIGoFV4K6WQ8JlftXXF/RTx64QaoHWMwXHCy++/RTtIIr6CLMwFoCMACV+iurd4gwurI5z6Ev9pwsbdDNNtRtp8d13u2ywt7azqIAtpXdYcjbWqrerrpZXYH4oFE3alL1lE0VgFoRAjiqQGAB9nNGUwOQ5eCyb7Tc3S4MpMq3EovFrNg9zH+LsFTGBMB6W4hrOgs8ulICKJ+yi/IJDAhnOdNtC6KtRUH3/Oe40ji4ma3qRb9HBSn/5djPhpGzmcg55nAETrqMsF4Y7BfcV1QOEWsew1vePOm44qIQo1PzG2bxmkbYFxeGSedS6YZKOhfQsHQ+wOIS2t41JNVUgvson5dKzQJmGsoYNko2vhlrZa/AeyhmMYtrsVsTW0Nztl4BeaEt5rxWQnN97vSmv3foOQtafNpBL76uQgCK4rZySjCgTQhg2IJC+djtNoC8l028UXQVw6Pg57srd1e8qpFt4fEetU987TS7l5TbVkHlJmzCLDNgz1CeODElTu96MzvirGDAtm1dcnwJGQL6iXQ9imnMSWXy0lT17rK3be0CtmMAon44izs+8oazusxTjTVZT/4KwdFi/9FoyPJsj4VgpJIV01wwNrv/YxllW9zaxIsn0Pn8FF7PVHCSdThcBmdq/Ey80YKrxI35lOOcfs/a2/Y5iCae7yc7jxbw5gI10w6g5r317lKWhLWXrV5aLBtAcWU0G0ibFIYFYEBUWTsxG7C4oOd27Ckgb2m+igbUPY+qqfX0xlFsBWl0wfPkpIS1OZ/686Vlzd8z+bSJN+8QeQf1BsguR2lS1U3KPe5u4LRx7MOPrmo+953vei0sswJei+jKlb88tT23Xio5rxFFpbf38JyGYANG3FCmepHzjndJWE/LylMrb90Q69caD+kQKITeAId5qc42th1fRdr9V7q250mOjf+D8PWZC7je7k3c4vQXhFVV8Qke3eAek22YVMFX2dTC4KmA7QlZhtmbGGxFXzRPdg2SzD3exc3OfJhZcRVecB0XWzUPnX0c4AwR+x0Xn43B+r3gnBlK4VlbW40PCzKa0W3gcbEZDvKNgfUeAflS8E0EJZjZ3uxcjLjVUvkgqj2bUz1f4MTH3hRX1HkP4LgALPGNrqHB6DCC03mR/GzLCJxSI8RUG7JGCwQBHFqFQ5GXCtgUQ8WUERTJDZEQZD1UYf3LCNzQC/ghqnUBFPjTvzBMALHdH+kVCAGXzeXC91ShDuIhVgEOFzzhuwneDfZF8jiPZN3OTCkbDV5ZARgOGaz/YKMp0B2RoE2wDWyI1gmtE0rdCGxw2vOt01C9QJvFADOh1GThIUuxE0HFAC7i4jHK10/54jPWmTIl0/7Q4kYhnBrMzSahlC8uozVVScEYgC4yHjO+lFX0hz01YzZRRU6x4/PBRgE5zib5ouJFIriBkJLASytM23QIADQAjgjiACI2HiQeixIcFTcqxk8x4zyyk7vdjTd2gTIR4zQ+ljEmk2RVVjaJiBIwxjJp1jI22us4nix2A7IJjmj10DgWTRLqhkmeAnsYjo3cAPHc0oGloYtchktNh8NY1PdRGTcRpJIEjvehCd9AQE3KgCM+IiaMJA4Y4w0Qo9KwpG4oAUp6/4Y1NZMMgCSwPV0iBaWLzM3BmUVRIZVVflvCWdBU8lFX5kMs0oBBXQJcygkADlBTLgRGoJJZ7CHXtBAjOoVaPkp4yIBgNsXrgJ8jsIJZstAiDCZSmko9AgajQKYRNAVdYgoCpBJmNoVmDSRTumUNeNtMRF0mESXPWcXHXQRgQtAr9sytVIQ/GMmSWMJh3qUz9UNGwdqN6BSMPKVHqhOuUMEM+CIKXKRV9INosVRfKKRtBmcUfWUlLECNfUaqrFFUuAGNeIOv2KVdxkBO2l5PPdRmiRSAhNRIUcl7JFYdUp8SQQFmjo4TSBYU/GRZndIARoFGyWbMmc8qqI5J1aFCif/n3ZwSgDqMAH1WLp6ABx6BOzWEOnnCaXhOOh1oF4jWP+3haTCWQC3ObLIlmeHCFJ2CkFFGGCSDHgjAA9SBAiBEeoAI2ZyAk13FidYBVIBIW0gRBFCZKzyAYS0AipqdVo3oeI3o5TGAASSAltTDAxCGAjxAZbzFGBycZR7YW7RUXuZkRi2oeEqCfzZjP0iW9hEbDzRAQt3IUIzDJzjBMqojCbSAgA4iek4RUHqmN2ygPhZZeTGBWqkfl92O3qRAyh1Zeo2ml60CjhrOKRVq8BBT/qnedQHk11zjGgSCBzlC2ZAcITyBQolAa2BqQnmB5eGZA2BIMTyHYSXICRxlA0z/QUT4g63Bx6i2kOVFnnZcwamChOXJDG1SBCUEAl1ER4nq5liURBPAxksGq3sQR4w4A0o4QTF6RYYVSQKMSBS4mQoM6x+kRmaQqqhG6qJcgiIoQk6Aqnc4QBYgguUxwXdkAWUEAMn9YiMsQ0yU6xJI1xYoQB1YpxG4ArzA6yteamOgGL1qwSvYi3POaTcoYJQpoLsFyJoFHKHtoqctbKghH7VhWtlcFlmFo6h+z1IV2LadW356KBuIwhwMbEs4wAPcDSiMzRGo7N9ZJZQuRrV2wQ0J609YhwtQgsxS6fOJalr8Q7hqF1fepH6mRg6oaB+UKEhM0VhMV2JqAtNeETiQ/4JZSYJyPis76N0asR7hTV1nKMMXrKrRxsAiwcUImcBt7A8EqM4UKYETsG2HnGeZaUfd1mG5dMIc5Ktv1EGKpZCefa1GeEFndCZalmTw6FvOiRotsBolUpXixpp8bRW1EU+Tdiy2zZ3LlSakkq0anE8L6EQXJNAURAl55RO6vELpxi0C1MKbKAKlugFbLNpg6GzOaleK9cQLMOmYAu1Z7CqHFq2H8urlNAAZlChRjIVweKuYngU4DO6F3CWA0dFNKG+HtNBaNEFuOgfrAVO30hEbqCp8AULr6gFC8MAUtelVmG9+MIYADe6qtoCIzupd0kNobAOU9qxmGFazioZviP/kZ3KnIX6P7REfCRiAVCGBTdUcARZwA3jBHVjfCzTASC3V/ZwPEySs/pHc9xzgo1qCasYAy56SHFjr3DaACNyD8wkBljAJNPRHNlztNnAJQQBrToztbnXF9jJXkeRqhz7Wd7gZAmBq5D1BKtQuu0oVQEjoAmQWyWkCEo+FTYhUs1KElAQAAhhW1t5GE3PkBNcBE7/t6a7HdVgPL0lpDbjtVYTn+USHd8wvHrYEfJYwDKDo9nyUGURFVeztPQgIN9yE4A6OdgLwZ8aAJgZPJ27YKi5wE1pr4EDGFIaVUYYJ7nxhx/LNc1liDoqspVUCl9iBFoDoASRIP46AfpxoQk3/yRXcxonWmEKcBVucaC5AAGWYmO1K0X80aQwwqZb07nO4QhKj4T12UJviQoayKYAeVRRAwb/U4XxYaBAQ5kWhkgtEM3quLOicUnoQpmbeJ2cJlEUBFmaxgFVIwn2yZmm5ZiVQaQmsci4vAAMwQCEI2RRJ6zvHMx6EMgyUsUSIqAIkwESkchDk6xiM5+g8k46O0XnscsHC4sF6QzRiyWFF5EQlpPYVDERGJEUqEWeegFEdBk2lk2YxZDVuMjoDmwl9I9qBDjPp5kP2Zpn2A3kmaD3tj2I4s5tKBg5s2E0bJ0QlaDDLALXEEc8IrffmMBvI5UwbI0ejI2ei4xssk1BJ/9NlfVY2UbU7FSODDuZhbNhPXxZVQKicGu4DgXDLmO2f+DCiYE7QnHHOBLBDL6UElbXKfHXapPUlPSfSELIvbOde685cYw9tso4+JLX8ZGVl5nVdDrJFaGY+vM6NOKaLAHYlVPME+bXLEK0wv4ADQEMCSGem6FIwRrY9xsnzba4+tPUvNLadlApH29hizwBaSStNCAY5cS7wwpyN/aVRXwLVTibhehM33REOW6MaCFPKomxWbzRxY1PBUAJoHbU5bvVvJqNiEmP64mF/FGczcsZLjyBplyQvjJPPLJKF2ICFtEir9LUjGVU4Vym8mimb5mWEOnOWikgyyffd6Ikx7/90I2RzMjWEUX3zQi1i3dR3PIYzY+G3VYglR+Vkf/D3PwEoYo0AXJ6SlAy4GGwYw9zCDU0UsYVjMc70OxaMh7uvgbfUhPsnfXt1UKXGvwDolS5vUMOAsfLIPyeAQHt2LhPpErTeSYRELigpijLXiqpikJ4o/w35jEom2ZiYVF0xjlPUjodBDhBCP85hdN7zkbuoi6otUTQrSaZzP6Tnm2p4fQrUfAtVQoW5hwOIiAjQc9v3TblTS3yWQWFoXmIWxZCNMmVzmjdCn39pTwl0FLj5e5fgWAvvK+T4pyIAvgrGvyYTviDAubKFaiiEpA8tD0yxdEEDfDhBQpWRqlarpef/qU48uqsugRjjAsl5NhYPQb/WwCcJWbn+QKfzgCjEKRJPw0VtATCZOqbDCDEQbBDMa5oOTjnkgiuQ+sCiAC+4arDzuqv68rheJxBcuro6kDDpSVsYqQ4frY0nE/96pLBGK0XJZERGMfQyl3kEAZTiYWbkgLczgSYowrXO9hXkeEFohkmjhSGG+v6K8agTgaNDupAJ8Ri5bR9M1/VSBbbnqammQPWeAhzUKlvl+IYmxZSEx68XKao7A8cTg6VeOHMVu8EnulgbLSWws41HxQipQuCmsRNUAR4C7tB+O/Tuxw3HRn75lBMUdWooAJK0xXlEBF74bfCaNKXKFGsIAkco/2lL5MCqIu3Pv+3ZtOmsnSpQlQsVf+14BPKbAIXVRz1z55fDz7yXiSC3n81AgDslaIIqKmlCU4VnTy01KO4tSO26I0PtIqu8WwMO++/T6pwY0NsUBH1t/vsK3PDQZy88qK1LUGokkMcTmNUt+fzblobN+kEOwGZECG113IJOzFvkd0bW70LlJ4jpp3xcr3wOs+6CbcRt7G/gZlH6mgHtCyzW5vDvTu/X3j4qcW1O268O469YbnrK10TV9kYKsO8UyELvoy8qLcUrxEt6HOn8BsLzOm2vQ8h6BP9pjK72RsTwh7/68qYPV290rOpivP1R44X9Iq8Mt9AtzD84UOqwUv8CdCQJCBBAMACLARTLWAIK8iDAPCNDUsyCsuQ0MAj8fqSfiBacBYtAoY0gAAim0WZgQZUlh6KBgmpAJBCB4+nFkla7QsCRNp1BqYBnNK5m6gTXbH0A9bM1RFg4aNh25MDgUyASF4SXdPRFU8AkKfSWAlHD0DSz0HbZMulSlVKZ4jbD4BCac4RH6VVoZAta01JQ0Fn3mVTkw8BXcpKmmqIHJ2AA0YhZBeEql9ZksKLGNZPM2xr1JqIae2rpk9BmXbgJcIAVgLAi8BDwcLcWSsbUgC4gyspAQQAGIpwFOOCODIMAeAIOFLFMBYJ45JQs5DMrzbx6Ua40oJhw4MEe82b/OEKFJN2QZf9SUDNBSkmARo8EIFAg01mjXLe6bVHEY0aRjGhY/cDT0luKmnt0mpziNAVNQSpxIcIVTwEKAgoYJDDgbh5OSCPn/fPioECCLwkOMAn74B87AQO8otjCb4cDJqbUsj1gIAGDgEAUOAjMYAA+bUYPEEBhlR1VQWyl1P0KqsiDLwvclhAzr4RfAW2X7amDRYECtQETVGHwrBpfIQoeeEVZOO1a0gc2+zuQmxViwiJGt10wGAcN07eGFEBgEzLDNgHaVDEgoEEYGg34IEBRxUGzKgyBGxDfYEQ68dgBbP9RwEFaHT+gp69O//10oQnk+zifHQAOACcggccM/3EIES3MkJdhiClmTRBwjSUAawz8E88OOCXIinEHgPbAEScJVUJGYSnATh8IIefVhCNgcUAcdNEVYxQZquZiSlZZxSENbs3khgHpXEKgASgckIOQBSApFGRu5bAkDUoyWZV76TBpUgAoRNlODlcCKRSBI0gH2QgzGCkUiTsaddUPbkl5JZQEPplCkUiKSSeXP6CpDIGXGAmZnkJwiSVgLxHhJJh0NmlmmGnOsCh+CuIi2ZqWXoppppruyNyON7VJiGl/LhfonFAedKZ0S0Jjaqg+KipEnCaZJ12WvRAi5HKjoHqmEHwq6V6gvBKJYJWX9rjOpsouy2yzk+1YqUzOTv9LbSFdJeZDtct2Wo223n6r7HuYfgfqSguCiy6mHA0gQ7qZIrsmvCu5S2+9j0KLi7z2unuJsfuGeu42/w5M8LH+clswum6VmXCxy+rbcMT1RsuTxBb/izDFF2/sLbIIcwwytRDb0qOQYlaLW7PiaiopwRSPPDCfl2IZciEZ14yzth4HvLG/tuiZ87ObJljAA4oFZSnPyRJywCcsK20pHmpOnK/PDfOR6QM5QA1yxtV9DXbYYo9Ndtlmn4122mqvnTY6tnycsAE4YdrAKxMFraOyCRLjo1BYBwsdCgYQcNCqQnTXTDXPCTCfGFq6x3iSRiIJ3Xyi+pcmkPapEXidfo//4pYAfrI3gg+AKcowm4TAjHGd2J2cAnqeOyAKoPf2zPUAuu/Oe+++/w588MIPT3zxxh9vPOzLcd0wmpS/MgR2oncZGNZtyLwx6w7/AEHqG9kjxRgOlFCGTVckUMJCDfTAygF7jS/FOwcM8FEC4QvmfgDwR7TAROwToLsDqEYkpEHA/kpED/BdwQHrM0AB2MWPMNiPHwUoyoFo8DKrFcwZdRgDAnxhkjEMpA4PAIJi5ucrEOIObywcGNwKZhgTLGQA0INUAhpQNxO4BQp7aUEMQaY9oXXrB+xTAWOOcIQAKCcF3ZHLmaADER/yQYkMmZt7oKiOX7RCBo9xTzZOw4oi/xRxBUxwBQyqUwnVdGYEE+RZBkMGAxe84lbLuWAMH5AeozSghF1jXgv/SK0XEqwzHATAoaSgtTN14gD2Y0xbQhbEvNGgewJjRUaM8pYF7MVtIhADGaKohC9ABQ+eLEMW8RCHJJ4rI0UIhzWooJgpJKKG6MAjId4IMmo8co9DIM0aHxmbMtZwhYAsJrgE+a9b8RIAj7QEDwZQAF4uQlp0BKIGqzaEZADnkYE5YreiIS02yEaKlsjEOH+wTAWk5whRKQArS8BN+zEBjzawhAsuRCAbfLE55bpYW+h4yGFUaJGNFIDTmskxZBpzoZZSqL14SY1qmmQG6KCGLd2Qg2Va8/9hVXng0VaQlxt6MzeZNIsmOjiP4kAgOx4ipWtClMXCKKAFb5jRAGp0zpDeZxoz5YZiHuCAelJwBhBoVyVXd81kdmKZbqOBYLDFywOsFB4rTYAKicnQrDLLofXSJXAacC5saIiZwHkA+BawGQgMM3tJ7WevynSJ/9SqSXqakpcgFStb4VVyrzIT0CAlJpUAi0+D8hOYSICQPT0OdSlg3y2xybEoETZURYIMsJ6kPItxVaucnRrHqJQq5zyuUSMAzp9oxrFISquz9eKq1I66PdYWc7OyZShta9sw1VYMt97665pQy0+k8vaPtx1uC4tr3H3pVrfJ3Rcum4sz5EK3ZtLLnS66lttW6w7sudrFanc5W93vVgu74uUYd8vbsPCit2DqXS9H3+veiJ03vhjzI31D1t77Ymq5oqSCf/8L4AALeMAELrCBD4zgBCP4Zf1VsIMfDOEIS/jBPdUvcbEw4QxreMMcNnBLNgWdDot4xCSOMFZKjOIUq9i/RrUw3qS34hjLeMOpc7GNb4zjHOt4xzzusY9/DOQgC3nIRC6ykY+M5CQreclMbrKTnwzlKEt5ylSuspWvjOUsa3nLXO6yl78M5jCLecxkLrOUQwAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The recommendations are based upon the availability of a team that includes a pediatric urologist/surgeon and pediatric anesthesiologist. If pediatric specialists are unavailable, surgical intervention is delayed until tertiary care access is available. Birth examination occurs either at delivery or the initial newborn examination within 24 hours of delivery.",
"    <div class=\"footnotes\">",
"     US: ultrasound.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Adam Hittelman, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_19_19775=[""].join("\n");
var outline_f19_19_19775=null;
